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ABSTRACT 
 
Annually, over $2.5 billion is spent on more than 500,000 bone grafts in the US alone, 
with more than 2 million being implanted worldwide. The limited supply of autografts 
and complications associated with traditional alternatives leave much to be desired. As 
of late, bone tissue engineering has developed as a promising alternative to these “gold 
standard” strategies for bone regeneration, effectively combining a patient’s own cells 
with biological factors together on a supportive construct to promote and induce de 
novo bone tissue formation. Due to the complexity involved in such an approach, its 
pathway to clinical application is wrought with numerous regulatory demands, all of 
which must be met in order to secure FDA approval prior to realization of clinical 
relevance. Key among these is the ability to monitor tissue engineered constructs, being 
able to effectively track such key aspects of construct quality as cellularity and degree 
of maturation (differentiation and mineralization). In the field, current methodologies 
for the determination of said aspects require the sacrificial destruction of the cultured 
constructs, an obviously infeasible practice for regenerative medical applications. As 
such, the main objective of this study was the development of alternative strategies for 
the real-time, non-destructive monitoring of bone tissue engineered constructs. 
To this end, constructs comprised of 85% porous poly(L-lactic acid) (PLLA) 
spunbonded fibrous scaffolds were dynamically seeded with 1.5 MM rat mesenchymal 
stem cells (rMSCs) and cultured within flow perfusion bioreactors (providing for the 
mitigation of nutrient gradients and the beneficial introduction of shear stresses 
throughout the construct) with either basal or osteoinductive media for periods of up to 
14 days. Throughout the culture period, oxygen concentration measurements were taken 
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at the inlet and outlet of each construct and global media samples were taken and 
assayed for glucose and osteoprotegerin content in order to determine oxygen uptake, 
glucose consumption, and osteoprotegerin (OPG) production rates. As specified time 
points throughout the culture period (Days 1, 3, 5, 7, 9, 11, and 14), constructs were 
sacrificed and assayed for cellularity (via a dsDNA assay), alkaline phosphatase (ALP) 
activity, and calcium deposition. Comparative analysis of trends in both the non-
invasive mid-culture and destructive post-culture data revealed correlations that can be 
utilized for the real-time, mid-culture determination of construct quality. Key trends 
observed include increases in the cell-specific rate of oxygen uptake and decreases in 
the cell-specific rate of glucose consumption by osteoinduced constructs with little 
change in non-osteoinduced ones and a steady cell-specific production rate of OPG for 
osteoinduced cultures as compared to significantly decreased production rates for non-
osteoinduced cultures. The opposing trends for oxygen uptake and glucose consumption 
of osteoinduced cultures can be explained my metabolic shifts in differentiating MSCs, 
a phenomenon which has proven useful in the development of monitoring metrics 
herein. Utilization of the ratio of oxygen uptake rate to glucose consumption rate as a 
key determinant of construct quality has proven promising in the analyses performed 
herein, potentially allowing for the elucidation of both a construct’s maturation and its 
cellularity non-destructively in real time. 
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1. INTRODUCTION 
 
1.1 Background and Significance 
1.1.1 Bone Tissue Defects 
Bone tissue defects effects millions of people annually, requiring in excess of two 
million bone graft interventions (with over 500,000 of these being required in the US 
alone, at a cost of over $2.5 billion) 1,2. As daunting as these figures seem they are 
expected to double by the year 2020, exacerbated by an aging and increasingly obese 
population, leading to particularly high projected increases in the need for long bone 
and spinal fusion procedures 2,3. 
Common defects requiring surgical intervention span from simple fractures (suffering 
from non-union or delayed-union complications) to mass resection of bone tissue as a 
result of malignant tumor formation 4,5. Furthermore, bone grafts are often implemented 
alongside implanted devices, as a means to aid in the incorporation and mitigation of 
immune rejection thereof 6. 
 
1.1.2 Bone Grafts and Alternatives 
The “gold standard” for bone grafts is the autograft, a section of bone obtained from a 
donor site elsewhere in the patient receiving the graft. Such a graft has the benefits of 
complete histocompatibility and intrinsic bone-supportive properties 5. Numerous 
limitations, however, exist for autografts including scarcity of viable donor tissue, donor 
site morbidity, and the requirement for two surgical procedures thereby increasing costs 
in addition to the potential for infection. 
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In attempt to overcome some of the limitations of autografts, many people rely on 
foreign sources for graft supply, obtaining donor tissue from deceased human cadavers 
(allografts) or other animal sources (xenografts). Although these two sources do much 
to push beyond autografts with respect to availability, they are still subject to supply 
limitations. Furthermore, the introduction of non-native tissue to a patient brings with it 
numerous complications including the possibilities of immune rejection, infection, and 
disease transmission. Additionally, these grafts require extensive processing to remove 
the cells and other immunogenic material thereby rendering them much less osteo-
potent than autografts. 2,4,5 
Non-tissue synthetic alternatives to the above traditional grafts have been employed to 
great extent due to their ready availability, ease of manufacturing into the specific size 
and shape required, relatively low cost, and elimination of the risk of disease 
transmission. These grafts are typically comprised of various calcium-based ceramics, 
metals, polymers, hydrogels, etc. As a result, they often exhibit good osteoconductive 
properties and can exhibit some beneficial osteoinductive ones, but due to their lack of 
cells they lack the osteogenicity afforded by autografts. Finally, depending on the 
specific material selected, the site of implantation, and the patient himself, a synthetic 
graft may elicit a foreign body response from the immune system resulting in graft 
rejection. 1,4,5 
One final type of graft seeks to mitigate the limitations and complications of these 
aforementioned grafts, while incorporating as many of their benefits as possible: the 
bone tissue engineered graft. Although not currently available for surgical intervention, 
these grafts are being heavily researched as of late and have shown promising results in 
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numerous animal models 7. Essentially, they seek to combine synthetic grafts with a 
patient’s own cells and potentially additional growth factors to produce a construct 
which is osteoconductive, osteoinductive, and osteogenic in addition to overcoming 
supply limitations and the risks of disease transmission and immune response. In order 
to achieve these numerous benefits, bone tissue engineered grafts do result in slightly 
longer preparation times and higher costs than the above-mentioned alternatives (the 
specifics of the bone tissue engineering approach are discussed in detail in Section 1.3). 
Table 1, below shows a comparison of the benefits and detriments of each of the graft 
types discussed above. 
 Autograft 
Allograft/ 
Xenograft 
Synthetic 
Graft 
Tissue 
Engineered 
Graft 
Graft 
Properties 
Osteoconductivity +++ ++ / +++ ++ / +++ ++ / +++ 
Osteoinductivity +++ + / ++ + / ++ ++ / +++ 
Osteogenicity ++ 0 0 ++ / +++ 
Associated 
Risks 
Infection Moderate Low Low Low 
Disease Transmission 0 Moderate 0 Low 
Immune Response 0 High Moderate Low / Mod 
Constraints 
Supply Low Moderate High Mod / High 
No. of Procedures 2 1 1 2* 
Time to Implantation Hours Hours Hours Days** 
Cost Low High Moderate Mod / High 
Table 1. Comparison of Graft Alternatives 
Graft properties (top) demonstrate beneficial bone-forming capabilities (more “+” 
corresponds to effect); osteoconductivity is the ability for a graft to serve as a viable 
construct for bone healing and in-growth, osteoinductivity is the ability for a graft to 
induce the differentiation of stem cells into mature bone cells, osteogenicity is the 
ability of a graft to itself produce new bone 8. Associated risks (middle) demonstrate 
potential complications; higher risk of infection in the autograft is due to the 
requirement of multiple surgical interventions (increasing the amount of tissue exposed 
during operation, potential disease transmission in the tissue engineered graft is 
associated with supplements used in the culturing phase, immune response (or foreign 
body response) is associated with the introduction of foreign material (either natural or 
synthetic) into the patient. Constraints of each graft (bottom) represent relative 
limitations of each; supply demonstrates the amount of graft material available from 
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each source, time to implantation takes into account the time from the start of the first 
surgical intervention until the end of the last, cost takes into account the cost of 
materials, labor, and (in the case of tissue engineered grafts) the additional culture 
supplies and labor required prior to implantation, and the number of surgeries represents 
the number of individual surgical interventions required (autografts require two, one for 
the removal of donor tissue and a second for its implantation to the grafting site). 
*Tissue engineered grafts require two procedures, although the first is a simple 
minimally invasive bone marrow biopsy requiring little time to complete. 
**The time to implantation required for tissue engineered grafts is displayed as days 
due to the extended culture period required from the original bone marrow biopsy until 
the final construct is implanted into the patient. (Compiled from 1,5,9). 
 
1.2 Bone Physiology 
In order to better understand the bone tissue engineering approach (detailed in the next 
section), the target tissue it aims to create must first be understood. Knowledge of this 
highly complex tissue also allows for the development of methods for the determination 
of the quality of such engineered constructs. 
 
1.2.1 Function of Bone 
Bone, comprising roughly 15% of the average person’s mass, serves numerous 
functions for the body 10,11. Far beyond providing simple structural support, bone also 
provides protection for vital internal organs and contains attachment sites for muscles, 
tendons, and ligaments to allow for locomotion 12–14. Furthermore, bone serves several 
storage functions: it provides a reservoir for marrow (wherein blood cells are produced) 
and minerals (predominately calcium and phosphorus) in addition to acting as a 
sequester location for several dangerous minerals (such as lead) 12,14. Finally, bone has 
homeostatic balancing functions, predominately acting to balance internal pH levels 
through the absorption and release of alkaline salts 13,14. 
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1.2.2 Composition of Bone 
Bone is a highly complex tissue with numerous levels of organization. It is typically 
classified into two distinct categories based predominately on the porosity and meso-
structural organization with cortical (compact) bone, being denser, and cancellous 
(spongy) bone being less so. These two types of bone will be discussed further in the 
next section, but first an overview of the microstructural aspects shared by both will 
now be discussed. 
There exist three main types of bone cells, each with its own unique function: 
osteoblasts, osteocytes, and osteoclasts. One key feature of all of these cells is that none 
of them are capable of self-replication, meaning that they are all derived from the 
differentiation of precursor cells 15. Osteoblasts, differentiated from mesenchymal stem 
cells, are responsible for the formation of new bone through the secretion of osteoid 
(predominantly type I collagen), and subsequent mineralization thereof. They also serve 
to manufacture hormones and several proteins, producing large quantities of alkaline 
phosphatase 15,16. As a result of their role, osteoblasts are mainly found at the periphery 
of newly forming bone tissue (periosteum and endosteum) or defect locations 15. As 
bone deposition occurs, some osteoblasts inevitably become trapped within channels 
(lacunae) in the newly-formed tissue, these then undergo alterations, transforming into 
osteocytes. These cells, comprising up to 95% of all bone cells, form dendritic 
extensions between each other through small channels (canaliculi) which also serve to 
allow for nutrient transport 17,18. Thanks to their internal location and high inter-
connectivity, osteocytes work to regulate mineral concentrations within bone via the 
secretion of numerous enzymes while concurrently regulating bone formation and 
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maintenance via the signaling of osteoblasts and osteoclasts 15–17. Completely different 
from osteoblasts and osteocytes are the osteoclasts. These polynucleated cells, 
originating from hematopoietic stem cells, resorb bone previously deposited by 
osteoblasts 19,20. In this capacity, osteoclasts work alongside osteoblasts to continuously 
remodel existing bone and heal bone defects 12. As such, osteoclasts are also 
predominantly located at the surface of bones or at defect locations requiring resorption 
and remodeling 15. Table 2, below, summarizes these different bone cell types. 
 
 
Progenitor 
Cells 
Predominant 
Location 
Key 
Phenotypic 
Features 
Major Functions 
Osteoblasts 
Mesenchymal 
stem cells 
Bone surface 
Defect sites 
Cuboidal 
Osteoid formation 
Mineral deposition 
Osteocytes Osteoblasts 
Bone interior, 
Lacunae 
Dendritic 
extensions 
Mineral regulation 
Remodeling regulation 
Osteoclasts 
Hematopoietic 
stem cells 
Bone surface, 
Defect sites 
Poly-
nucleated 
Bone resorption 
Table 2. Types of Bone Cells 
The three major types of differentiated bone cells fulfill very different roles, giving rise 
to their varied locations and features. 
 
While cells comprise the living component of bone, giving rise to its adaptive and 
regenerative properties, they only account for a mere 2 – 5 % of bone by mass 12. The 
remainder is composed of proteins (~25%), minerals (~70%), and water (~5%) 12,14,21. 
Figure 1, below, details the relative amounts of the acellular components present in 
bone. 
7 
 
Figure 1. Acellular Composition of Bone 
The main components of bone (percentage by mass). The amounts of each component 
relative to total amount of each within the average human are also provided, 
demonstrating the important regulatory/buffering function of bones. (Figure copied 
from 22). 
 
The main protein found in bone is collagen type I provides the structural framework of 
the osteoid, giving rise to the flexibility of bone 21,23,24. Several other proteins, 
glycoproteins, and proteoglycans are also present in bone. The most abundant of these 
non-collagen proteins is bone Gla protein, also known as osteocalcin (BGP or OCN). 
This protein is specifically secreted by mature osteoblasts and osteocytes and is thought 
to have important roles in bone remodeling 23. It mainly binds to calcium present in 
bone mineral, but is also present at lower levels in the extracellular fluid 24–26. Another 
important protein present in bone is osteoprotegerin (OPG, also known as tumor 
necrosis factor receptor superfamily member 11b or osteoclast inhibitory factor). This 
soluble protein is secreted by both mesenchymal stem cells and osteoblasts and 
functions mainly as an inhibitor of osteoclast maturation and activity 27–30. The main 
glycoproteins found in bone include bone sialoproteins, osteonectin, alkaline 
phosphatase (ALP), and the bone morphogenetic proteins (BMPs). The first two of 
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these are important in directing the attachment of bone mineral to bone collagen, ALP 
aids in the regulation of phosphate levels and mineralization (and is often used as a 
marker for the presence of bone), and several BMPs are known for their osteoinductive 
properties 24–26. Finally, the bone proteoglycans have been shown to play significant 
roles in mineralization of osteoid. They are thought to serve as spacers in newly-formed 
collagen matrix, being later cleaved to allow for mineral deposition 24–26. 
The inorganic mineral component makes up the most significant portion of bone. This 
consists mainly of calcium, phosphate and carbonate with small percentages of 
potassium, sodium, and magnesium 22,23. The predominant mineral structure is in the 
form of hydroxyapatite, Ca10(PO4)6(OH)2, crystals no larger than approximately 20-40 
nm in any dimension (Figure 2, below, shows the unit cell for crystalline 
hydroxyapatite) 21,23. This crystal structure is not perfectly crystalline, containing many 
carbonate substitutions and being interlaced with other crystalline forms of calcium 
phosphate 21,23. It is this crystal component that gives rise to the rigidity of bone and its 
mineral regulatory/buffering capabilities 21,23. 
 
Figure 2. Structure of Hydroxyapatite 
Hydroxyapatite, the main component of bone, is a crystalline structure with the 
unit cell depicted. Note: the eight hydroxyl groups present on the vertical edges 
of the unit cell are depicted in full, though only one quarter of each is actually 
contained within the unit cell. (Figure copied from 31). 
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1.2.3 Structure of Bone 
Bone tissue is traditionally classified into two different categories based on its porosity 
and architecture. The first of these, characterized by higher density and more parallel 
alignment is cortical bone (also called dense or compact bone). With a porosity 
typically between 5 and 10%, cortical bone provides rigidity and tensile strength for the 
shaft of long bones, and the outer shell of most other bones 14,32. The structure of 
compact bone is highly organized, consisting of longitudinal osteons each containing a 
central Haversian canal surrounded by concentric lamellae 33. Osteocytes are contained 
within lacunae between these concentric lamellar rings, with small interconnected 
channels of canaliculi 33. Together, the Haversian canals and canaliculi provide a vessel 
network for the transport of nutrients and signaling molecules. 
The other type of bone tissue, cancellous bone (also called spongy or trabecular bone) 
maintains a porosity usually ranging from 75 to 95% 32. It consists of numerous 
seemingly-randomly organized trabecular plates, creating small cavities inside of which 
red bone marrow is contained 33. The organization of these trabeculae, however, is not 
random, rather they are arranged along the main stress lines in a bone, providing 
structural support against stresses and strains 33.As a result, cancellous bone is found 
predominately in high-stress regions of bones such as the epiphyses of long bones and 
the bulk of the interior of vertebrae and flat bones 32. Figure 3, below, demonstrates the 
organization of both cortical and trabecular bone tissues within a long bone. 
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Figure 3. Structural Organization of Long Bone 
A typical long bone is composed of cancellous (spongy) bone in the 
interior (filled with red bone marrow) surrounded by a shell of cortical 
(compact) bone. (Figure copied from 33). 
 
1.2.4 Bone Development, Growth, and Modeling 
Bones begin to develop as a fetus and continue to grow into adulthood. The formation 
of new bone, or osteogenesis, occurs via the replacement of other tissues with bone 
tissue, a process called ossification (although the two terms are often mistakenly used 
interchangeably) 22. This occurs via one of two different methods: intramembranous 
ossification or endochondral ossification. The former method, occurring mainly in flat 
bones, involves the infiltration of sheets of connective tissue formed within the fetus 
(the mesenchyme) 34–36. This involves the direct differentiation of mesenchymal stem 
cells into osteoblasts, followed by the subsequent deposition of osteoid followed by the 
mineralization thereof, creating primary bone 34–36. Endochondral ossification, in 
contrast, occurs within most of the bones of the skeleton 33. In this process, 
mesenchymal stem cells first form a cartilage model for the bone to come; MSCs 
differentiate into cartilage and deposit cartilaginous extracellular matrix before inducing 
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apoptosis to allow for the infiltration of undifferentiated MSCs which subsequently 
differentiate into osteoblasts, replace the cartilaginous matrix with osteoid, and mineral 
said osteoid into primary bone 33–36. Figure 4, below, demonstrates the process of 
endochondral ossification. 
 
Figure 4. Endochondral Ossification Process 
Endochondral ossification is the method by which most bones develop. A cartilage 
model of the bone-to-be is subsequently replaced by bone tissue. (Copied from 37). 
 
The continued growth of bones into adulthood occurs via a process similar to 
endochondral ossification. Occurring primarily in long bones, cartilage near the 
epiphyseal plate (growth plates, located at the metaphysis) continually proliferates and 
is continually ossified, thereby lengthening the bone into early adulthood 33,36. Increases 
in the diameter of long bones (termed appositional growth) can continue on into later 
adulthood as a result of continued deposition of cortical bone at the periosteum (an 
outer layer of connective tissue encasing most bones) 33,36. Continued growth (in length 
and diameter) of bones without concurrent modeling thereof would produce oddly-
shaped, increasingly-heavier bones. To account for this, bone is continually modeled via 
the synchronized formation and resorption of bone on different surfaces 12. In bone 
lengthening this is accomplished via the resorption of bone by osteoclasts at the 
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medullary cavity as the epiphyseal plate moves; in appositional growth this is 
accomplished via the resorption of bone at the endosteum (adjacent to the medullary 
cavity) as it is deposited at the periosteum 33,36. It is important to note that the bone 
formation discussed in this section is all primary bone, also known as woven bone. This 
type of bone is characterized by its weak mechanical properties and disorganized 
arrangement of collagen 12,38. Woven bone also contains more osteocytes per volume 
than does its more organized secondary (or lamellar) bone, and exhibits a much higher 
turnover rate (as it is remodeled relatively quickly into lamellar bone) 38. The 
remodeling process is discussed in the next section. 
 
1.2.5 Bone Remodeling and Repair 
In order to produce the strong, highly-organized bone tissues introduced in Section 
1.2.3 from the weak, randomly-organized woven bone originally developed (as 
discussed in Section 1.2.4), it is obvious that some reorganization is required. The 
process by which this occurs is called remodeling which can be divided into 5 distinct 
phases. The first phase entails the stimulation and differentiation of pre-osteoclasts and 
their recruitment to the signaling area. Second, the osteoclasts resorb bone matrix in 
their local vicinity. Third, the osteoclasts are signaled to halt resorption. Fourth, 
osteoblasts are recruited to the area and begin to form and mineralize osteoid. Finally, 
some osteoblasts become trapped in the newly formed bone and transform into 
osteocytes while the remaining ones undergo quiescence and become inactive bone 
lining cells. This process occurs throughout one’s entire life to continuously replace 
older, potentially weaker bone with newer, stronger bone in addition to allowing for 
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alterations in bone structure to compensate for changes in stress patterns and load 
requirements. It also aids in the homeostatic regulation of pH and mineral balances 
within bone as well as throughout the body. A diagram of this process is provided in 
Figure 5, below. 12,39,40 
 
Figure 5. The Bone Remodeling Process 
The five phases of bone remodeling are activation/recruitment of osteoclasts, resorption 
of bone matrix, reversal of osteoclast activation, formation of new bone, and 
mineralization of osteoid and quiescence of osteoblasts. (Copied from 39). 
 
While the remodeling of bone represents a continuous maintenance process, certain 
events can elicit a more drastic, immediate response. Any significant bone defect 
resulting in the exposure of internal bone matrix (such as a fracture, complete break, 
mass resection, etc.) will invoke the bone repair response. This process occurs in four 
main steps, and can take up to several months even years to complete depending on the 
location and degree of defect and other factors related to the person themselves (such as 
age, sex, medication, etc.) 41. The first, immediate response is inflammation resulting in 
the formation of a protective hematoma around the defect site. This is followed by the 
formation of a fibrous callous within the hematoma via the infiltration of fibroblasts and 
mesenchymal stem cells into the area which secrete collagen fibers throughout. Next, in 
a process similar to endochondral ossification this fibrous callous is ossified into crude, 
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woven bone with the recruitment and differentiation of osteoblasts, osteoclasts, and 
osteocytes within the mineralizing matrix 12. Up to this point approximately two months 
are required for the entire gap to be filled with new bone (depending on the factors 
mentioned earlier). Finally, this crude, weak bony callous is remodeled over the next 
several months to years until the bone regains is previous structure and strength. A 
diagram of this process is provided below, in Figure 6.  12,40–42 
 
Figure 6. The Bone Repair Process 
The process of bone repair can be described in four main steps: hematoma formation 
(a), soft callous formation (b), ossification of soft callous (c), and bone remodeling (d). 
(Figure copied from 40). 
 
1.2.6 The Metabolism of Bone Cells 
The metabolic profiles of different bone cells can vary greatly due to their varied roles 
and locations within bone. This section will discuss the metabolism of those bone cells 
belonging to the mesenchymal lineage, namely mesenchymal stem cells, osteoblasts, 
and osteocytes (as these are the relevant cells to the project discussed herein). 
Mesenchymal stem cells, normally residing within an hypoxic environment in vivo 
(deep within the red marrow of bones), have been shown to metabolize predominately 
through glycolysis, though they do still utilize low levels of oxidative phosphorylation 
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43–48. Even when cultured in vitro in a more oxygen rich environment, MSCs have still 
been shown to favor glycolysis, though potentially exhibiting more oxidative 
phosphorylation that those cultured in hypoxic environments 43,44. This high glycolytic 
metabolism is consistent with the Warburg effect as has been reported for cells adapted 
to living in hypoxic conditions in vivo 44. 
Osteoblasts, typically present in regions of bone with higher oxygen levels, have been 
shown to have increased oxygen consumption rates compared with their progenitor 
MSCs 43,46,49,50. This has been shown to be the result of a shift in metabolic profile from 
glycolysis-dominated to a decreased reliance on glycolysis coupled with an increased 
utilization of more efficient oxidative phosphorylation 43,46,49. Moreover, MSCs cultured 
in vitro under hypoxic conditions have demonstrated a decreased capacity for 
osteogenic differentiation, perhaps due to their commitment along a chondrogenic 
pathway 43,44. Chen et al. hypothesize that this transition from a metabolism dominated 
by glycolysis in MSCs to one with a significant contribution from oxidative 
phosphorylation in osteoblasts is permitted by the concurrent upregulation in 
antioxidant enzymes during osteogenic differentiation 46. As a result, osteoblasts have 
the cellular machinery that permits them to reduce reactive oxygen species produced via 
oxidative phosphorylation, allowing them to benefit from this more efficient pathway 46. 
Osteocytes, located deep within highly-mineralized tissue, have been shown in limited 
studies to exhibit much lower oxygen uptake rates than their osteoblast progenitors 51. 
Although few studies have been published on the subject, the literature tends to suggest 
a return to a more glycolytic metabolism 51–53. Furthermore, some studies propose that 
hypoxia could potentially promote the differentiation of osteoblasts to osteocytes, 
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though this claim is not well substantiated as of yet 52,53. Figure 7, below, summarizes 
the metabolic changes accompanying the differentiation of MSCs to osteoblasts (and 
chondroblasts). Table 3, below, summarized the effect of oxygen tension on MSCs and 
osteoblasts. 
 
 
Figure 7. Metabolic Changes During MSC Differentiation 
Mesenchymal stem cells, present in a low oxygen environment in vivo, metabolize 
predominately through glycolysis (a.). If maintained within a hypoxic environment they 
differentiate preferentially into chondroblasts (b.). In the presence of higher oxygen 
levels, they preferentially differentiate into osteoblasts which can derive energy much 
more efficiently through the use of oxidative phosphorylation (c.). The resulting effect 
is increased oxygen and decreased glucose consumption by osteoblasts as compared 
with MSCs. (Copied with modification from 43) 
 
 MSCs -> Osteoblasts 
Hypoxia 
Mainly glycolysis 43–45 
Physiological ~4 - 7% O2 
Inhibited 
osteogenesis43–46,54,55 
Inhibition of growth 
and mineralization54,55 
Normoxia 
Balance of glycolysis and 
OxPhos 43–46 
increased proliferative 
capacity 43–46 
Mainly OxPhos 43,46 
with glycolysis 
Table 3. Effect of Oxygen Tension on MSCs and Osteoblasts 
Local oxygen concentration can greatly affect the metabolism, proliferation, and 
differentiation of MSCs and osteoblasts. 
a. b. 
c. 
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1.3 The (Bone) Tissue Engineering Approach 
Tissue engineering has emerged over the past couple of decades as a multidisciplinary 
field aimed at the production of tissue substitutes predominately for regenerative 
medicine purposes. At its core, tissue engineering seeks to produce de novo tissue via 
the combination of cells, biomaterials, and biological factors, typically cultured in vitro 
within a bioreactor. The general approach entails the following steps: extraction of a 
stem cell rich sample from a patient, separation of the stem cells from the sample, 
deposition of these isolated stem cells onto a biomaterial scaffold, culture of this 
construct in vitro (typically in a bioreactor, with the addition of biological factors), and 
subsequent implantation of the engineered construct into the defect site within the 
patient. Each of these aspects as they relate to bone tissue engineering will be discussed 
in turn. Figure 8, below, summarizes the key aspects of the tissue engineering 
approach. 
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Figure 8. The Tissue Engineering Approach 
The generalized tissue engineering approach entails the extraction, separation, and 
proliferation of stem cells from the patient (a.), the deposition of these cells within a 
biomaterial scaffold to produce a cell-seeded construct (b), the in vitro culture of this 
construct (typically within a bioreactor system with the addition of biological factors to 
promote the proliferation and differentiation of the stem cells within the construct) (c.), 
and the ultimate implantation of the resulting tissue engineered construct into the patient 
at the site of the defect requiring the graft (d.). 
 
1.3.1 Cells 
The first aspect of tissue engineering which separates it from other fields is its direct 
utilization of cells to aid in tissue (re)generation. For bone tissue engineering, a 
multitude of different osteogenic progenitor cells are used, each with its own benefits 
2,56. The most widely used of these is the bone marrow-derived mesenchymal stem cell 
(BM-MSC) due to its high degree of osteogenicity and well characterized nature 1,56,57. 
Other cells implemented for bone tissue engineering thus far include adipose-derived 
cell extraction 
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stem cells (ADSCs; as they are easy to extract and highly abundant), embryonic stem 
cells (ESCs; as they exhibit high pluripotency), umbilical cord blood mesenchymal stem 
cells(CB-MSCs), and as of late, induced pluripotent stem cells (iPSCs; as they are able 
to be produced following non-invasive fibroblast extraction) among others 1,56. Each of 
these cell types comes with its own complications as well: BM-MSCs are not available 
in very large quantities, necessitating extensive in vitro expansion; ESCs are surrounded 
with legal and ethical controversy in addition to producing teratomas in vivo; iPSCs 
require extensive reprogramming and expansion and are accompanied with safety 
concerns as well; and ASCs and CB-MSCs are not well studied, necessitating further 
testing of their efficacy for bone tissue engineering 1,2,56,57. No matter what cell type is 
used, the key characteristics desired by most include the ability to proliferate, 
differentiate into osteoblasts (and osteocytes), and secrete the appropriate matrix, 
proteins, and other signaling molecules required for proper tissue formation and 
incorporation 1,2,56. Some researchers impose further demands of their cells, also 
requiring the potential for vascularization of their construct (typically through the co-
culture of various cell types in vitro 1,2,56,58. 
Based on their high degree of characterization, easy isolation and expansion, and well-
established osteogenicity, bone marrow derived MSCs were selected as the cell of 
choice for the studies conducted herein. 
 
1.3.2 Materials and Scaffolds 
One field within the bioengineering domain which overlaps quite heavily with tissue 
engineering is that of biomaterials. This is a result of the necessity for a vehicle that 
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provides a framework for the development of a tissue engineered construct. The field of 
biomaterials, as of late, has proven a hotbed of activity for tissue engineering with 
research spanning from material development, characterization, and modification to 
scaffold design, production, and testing 1,2,58–61. There exist numerous classes of 
biomaterials in use already, these include metals (aluminum, stainless steel, etc.), 
synthetic polymers (poly(lactic acid), poly(caprolactone), etc.), natural (bio)polymers 
(collagen, hyaluronic acid, etc.), and ceramics (hydroxyapatite, calcium phosphate, etc.) 
to name a few 1,2,58–61. Furthermore, several composite/hybrid materials exist, comprised 
of two or more of these classes of materials combined in various ways 2,58–60. 
The choice of biomaterial to use is only part of the process; further attention must also 
be given to the scaffold. Such considerations as scaffold size, shape, porosity, pore size, 
and rate of degradation (if applicable) must be made. Furthermore, the method of 
manufacture of said scaffolds comes into play, as many exist. Fabrication techniques 
span from particulate leaching, fiber meshing, molding, casting, and of particular 
interest recently are several additive manufacturing techniques 2,58,59. Each method has 
its own advantages and disadvantages, such as the ability to tune porosity, the size and 
shape of the scaffold and its pores, scalability, speed, accuracy, and precision 2,59. 
The end result of this vast selection process is the development of a scaffold exhibiting 
the desired characteristics. For bone tissue engineering these are generally defined as 
having a scaffold with high osteoconductivity, osteoinductivity, and biocompatibility; 
exhibiting properties similar to that of the target tissue (which even in bone tissue 
engineering can vary greatly depending on the target defect location) such as hardness, 
elasticity, porosity, pore size, alignment; and displaying degradation rates compatible 
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with (on the time-scale as) the expected tissue production rate of the implanted 
construct (allowing for the gradual replacement of the scaffold with native tissue) 
1,2,58,59. 
The biomaterial of choice selected for the experiments discussed herein was selected to 
be poly(L-lactic acid), for several reasons. First of all, it is a widely used material in the 
field of tissue engineering due to its biocompatibility, biodegradability, bioresorbability, 
and its already being an FDA approved material 62–64. Furthermore, the hardness of 
PLLA is similar to that of bone, establishing it as an apt osteoconductive material 65,66. 
 
1.3.3 Growth/Differentiation Factors 
In addition to cells and biomaterial scaffolds, many employ the use of chemical 
stimulation to enhance the regenerative capabilities of tissue engineered constructs. For 
bone tissue engineering, most of these additives are implemented in vivo to promote the 
recruitment of native cells, their proliferation, differentiation, and secretion and 
mineralization of matrix, and the vascularization of the resultant de novo bone 1,59,61,67. 
The most widely used of these include the classes of bone morphogenetic proteins 
(BMPs; predominately BMPs -2 and -7; to promote migration, proliferation, and 
differentiation), fibroblast growth factors (FGFs; to promote proliferation and 
differentiation), insulin-like growth factors (IGFs; to promote proliferation and matrix 
secretion), transforming growth factors (TGFs; to promote proliferation; the family to 
which most BMPs belong), and platelet-derived growth factors (PDGFs; to promote 
proliferation and matrix secretion) 1,59,61. These are typically added just prior to the 
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implantation of a bone tissue engineered construct either directly onto the construct or 
in some encapsulated form to control the local release profile of said molecules 1,61,67.  
More relevant to this study, some chemicals are added to in vitro cultures to assist the 
proliferation and/or differentiation of stem cells along an osteoblastic lineage. Some 
groups have utilized osteogenin, BMPs, and FGFs, while a majority of research 
involving the in vitro culture of bone tissue engineered constructs utilizes the smaller 
and cheaper molecules: dexamethasone, ascorbic acid, and β-glycerophosphate 68,69. 
Dexamethasone, a synthetic corticosteroid not naturally present in vivo, has been found 
to promote the differentiation of stem cells into osteoblasts by acting as an agonist, 
binding to regulatory proteins (typically activated by natural glucocorticoids) which 
subsequently induce the transcription of osteoblastic genes 68,69. Ascorbic acid (vitamin 
C) is thought to serve potentially many roles in aiding in osteogenesis. It has been 
shown to be important in collagen secretion for matrix formation by serving as a 
cofactor for the hydroxylation of pro-collagen, facilitating proper structuring of 
collagen 68,69. Furthermore, ascorbic acid has antioxidant properties, providing a means 
for the reduction of reactive oxygen species produced via oxidative phosphorylation, the 
metabolic pathway highly utilized by osteoblasts 46. The main roles of β-
glycerophosphate in aiding in bone tissue engineering stem from its providing organic 
phosphates; the evolution of free phosphates serves to shift the balance of phosphates in 
solution which in turn provides a potential not only for mineral deposition (which then 
can further promote cell adhesion and differentiation) but also for the phosphorylation 
of key regulatory enzymes involved in the production of proteins expressed by 
osteoblasts 68,69. 
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The growth/differentiation factors selected for the experiments outlined herein include 
dexamethasone, ascorbic acid, and β-glycerophosphate due to their relatively cheap cost 
and extensive use within bone tissue engineering.  
 
1.3.4 Bioreactor Systems 
Although an approach does not necessitate the utilization of a bioreactor to be 
considered tissue engineering, most groups do employ their use. The primary purpose 
for the use of bioreactors is their introduction of a convective mode of transport through 
a construct, a phenomena which has a multitude of effects 2,70–72. First of all, with 
respect to mass transport, the addition of a convective mode allows for the production 
and culture of much larger constructs which would otherwise be subject to severe 
diffusive limitations with regard to nutrient transport into, and byproduct transport out 
of, said construct 2,71,73. Additionally, this allows for the mitigation (or, if desired, 
control) of otherwise potentially large gradients (of nutrients, byproducts, pH, cell 
signaling molecules, and even cell density) throughout the construct 2,71,73. Furthermore, 
such added benefits as improved cell seeding, automation of culture, and facilitated 
monitoring can be realized 2,74. 
Specifically for bone tissue engineering, the convective flow produced within a 
bioreactor has the added benefit of inducing shear stresses on the cells within (similar to 
their native environment) which has proven beneficial for the osteoinduction of 
osteogenic cells 2,71,73–75.  
Several different bioreactor systems are employed in bone tissue engineering, with the 
most widely used being spinner flasks, rotating wall vessels, and perfusion systems 2,70–
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74. The simplest bioreactor, the spinner flask, consist of constructs suspended in culture 
media which is circulated via a stir bar or impeller; such a system subjects constructs to 
non-uniform shear stresses and does little to mitigate internal gradients 2,72,73. A step up 
in complexity is the rotating wall vessel, comprised of a chamber made from two 
concentric horizontally-oriented cylinders filled with media into which constructs are 
placed; originally developed by NASA, these bioreactors exhibit fairly uniform low 
shear stresses while acting to reduce diffusional limitations through the constructs in a 
continuous state of free-fall 2,70,72,73. The most complex of these systems, the flow 
perfusion system, consists of constructs immobilized within chambers through which 
media is perfused;  in this manner such systems provide for quite uniform shear stresses 
throughout the construct while allowing for the mitigation (and control) of gradients 
present within said constructs though they typically require highly porous constructs 
with high pore-interconnectivity  2,70,72,73,75. Figure 9, below, provides a representation 
of each of the bioreactor systems discussed. 
 
 
Figure 9. Bioreactor Systems for Bone Tissue Engineering 
Common bioreactor systems for bone tissue engineering include the spinner flask (a.), 
rotating wall vessel (b.), and flow perfusion system (c.). 
 
a. b. c. 
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The bioreactor system selected for the experiments detailed herein was selected to be 
the flow perfusion system due to its uniform shear stress, mitigation of intra-construct 
gradients, and ease of implementing on-line monitoring systems. 
 
1.4 FDA Regulations 
One of the greatest hurdles faced by bone tissue engineering to date is that of obtaining 
approval from the US Food and Drug Administration (FDA) for the clinical use of bone 
tissue engineered constructs. Much of the complication in securing said clearance stems 
from the classification system utilized by the FDA in determining the appropriate 
regulatory pathway wherein medical products must be classified as either a drug, 
biologic, or device, each being regulated by a different center 76,77. Due to the complex 
interplay involved in tissue engineered products, it is often difficult to place them into 
one of these categories. In order to facilitate the regulation of such combination 
products, the FDA established that “combination products” shall be classified according 
to their primary mode of action with drugs being assigned to the Center for Drug 
Evaluation and Research (CDER), biologics to the Center for Biologics Evaluation and 
Research (CBER), and devices to the Center for Devices and Radiological Health 
(CDRH) 76–79. Even so, it is still often difficult to define the primary mode of action of 
tissue engineered constructs, though in general it seems that they will fall under the 
jurisdiction of CBER if it is asserted that the cells within the construct are the primary 
source of regeneration or potentially CDRH if it is found that the scaffold itself is the 
main contributor, although both these centers as well as CDER may become 
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cooperatively involved in the regulation of tissue engineered constructs 76. Though each 
center involves navigating different regulatory pathways, several similarities exist 78.  
Many tissue engineering applications (and certainly the project outlined herein) will 
most likely be regulated under the oversight of CBER, specifically under 21 CFR Part 
1271: Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) 80. This 
code establishes requirements for all aspects involved in the manufacture, distribution, 
reporting, and inspection of HCT/Ps 80,81. Key among these requirements is Subpart D 
current good tissue practice (cGTP) which sets forth regulatory guidelines for methods, 
facilities, and controls for recovery, screening, testing, processing, storage, labelling, 
packaging, and distribution of HCT/Ps with the main purpose of preventing the 
introduction, transmission, or spread of communicable diseases 80. Furthermore, 
oversight from CDRH will most likely also contribute to further regulations, namely 21 
CFR 861: Procedures for performance standards development (for medical devices), 
aimed at the establishment of standards for the safety and effectiveness of a device 82. 
These, among many other regulatory requirements must be met for a tissue engineered 
construct to achieve FDA clearance for clinical use. As such, it is important that the 
field begin to establish sound quality monitoring procedures to prove and ensure the 
safety and efficacy of tissue engineered constructs. It is one of the main objectives of 
the research presented herein to begin to establish said procedures, laying the 
groundwork for FDA approval of bone tissue engineered constructs. 
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1.5 Research Objectives 
1.5.1 Hypothesis 
The predominant hypothesis utilized in the development of the project outlined herein 
was that such aspects of bone tissue engineered constructs as quality, degree of 
differentiation, and confluency can be determined via non-destructive soluble analyte 
monitoring alone. Specifically, that trends in analyte rates of change (or ratios thereof) 
will allow for the determination of these aspects. 
 
1.5.2 Objective 1: Production of Bone Tissue Engineered Constructs 
The first objective sought by this project was to produce bone tissue engineered 
constructs via currently established methods (as outlined in Materials and Methods, 
Section 2.1). Additionally, baseline (non-osteoinduced) constructs were to be produced 
as a means of comparison. This objective was determined to have been achieved 
successfully based on the analyses employed in Objective 3. 
 
1.5.3 Objective 2: Mid-Culture Construct Sampling and Monitoring 
The second objective was to monitor key analytes during culture. Key analytes were 
first selected, then a means for their quantification was to be determined. Finally, said 
species were to be measured intermittently throughout culture in order to calculate rates 
of change of each. Both osteoinduced and non-osteoinduced constructs were to be 
monitored to allow for comparison and differentiation. 
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1.5.4 Objective 3: Post-Culture Construct Analyses 
The third objective was to determine the above-mentioned construct aspects (quality, 
degree of differentiation, and confluency) from constructs sacrificed after different 
culture times. This was to be done using established methods (as outlined in Materials 
and Methods, Sections 2.2.5 – 2.2.7). Both osteoinduced and non-osteoinduced 
constructs were to be analyzed. 
 
1.5.5 Objective 4: Development of Quality Monitoring Metrics 
The final, and main objective of this project was to develop metrics or correlations for 
the real-time, non-destructive monitoring of in vitro bone tissue engineered constructs. 
This was to be accomplished via comparative analyses of the data collected in 
Objectives 2 and 3 for both the osteoinduced and non-osteoinduced constructs. 
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2. MATERIALS AND METHODS 
 
2.1 Cell and Bioreactor Basics 
2.1.1 Cell Extraction 
The cells utilized within the experiments outlined herein were rat mesenchymal stem 
cells (rMSCs). The cells were extracted and isolated from the femurs and tibias of adult 
male Wistar rats approximately 6 weeks of age (175 – 199 g in mass; Envigo, 
previously Harlan Laboratories) utilizing established methods 83 as approved by the 
University of Oklahoma Institutional Animal Care and Use Committee (IACUC). Rats 
were asphyxiated one at a time in a sealed chamber with a rate of influx of CO2 equal to 
10% of the volume of the chamber per minute (the chamber was expelled of CO2 
between each rat to prevent premature asphyxiation). Immediately following confirmed 
death, the lower half of each rat was shaved, and the rats were submerged in 95% 
ethanol for 5-10 minutes to sterilize the exterior of each rat. Next, the skin along the 
legs was scrubbed with Triadine™, then 95% ethanol to further sterilize the area of 
interest. An incision was then made longitudinally from the hip to the ankle to allow for 
the excision of the femur and tibia, which were then carefully removed of all attached 
flesh and tendons. The patella was removed, and the two bones were separated before 
rinsing with cell culture media.  
Rinsed tibias and femurs were then cut at the distal and proximal metaphyses, 
respectively. An 18-gauge needle attached to a 5 mL syringe filled with α-MEM (see 
next Section 2.1.2 for details on α-MEM) was then inserted through the uncut epiphysis 
and metaphysis of each bone (the proximal epiphysis of the tibia and distal epiphysis of 
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the femur) into the diaphysis, wherein the bone marrow was subsequently flushed from 
the medullary cavity into a sterile 50 mL conical tube. The collective marrow from all 
specimens was then gently homogenized within the media, and split evenly into T75 
cell-culture flasks (one flask per bone), which were then brought to a total volume of 10 
mL with fresh α-MEM. Three days after the extraction, the media in the flasks was 
removed, the flasks were rinsed with PBS, and 10 mL of fresh α-MEM was added to 
each flask. This step was utilized as a means to remove any non-adherent cells also 
found within the extracted solution, such as hematopoietic stem cells and various blood 
cells. The remaining adherent cells constitute passage zero rMSCs. 
 
2.1.2 Media 
Two types of cell culture media were utilized in these experiments: basal α-MEM and 
Osteoinductive media. The α-Minimum Essential Media was prepared from powder (+ 
L-glutamine, - ribonucleosides and deoxyribonucleosides; gibco, Ref. # 12000-022). 
The reconstituted powder was pH adjusted to between 7.2 and 7.4 before being filter-
sterilized with a 0.22 µm bottle-top vacuum filter (Corning; Ref. # 431097). This 
solution was then supplemented with 10% vol/vol fetal bovine serum (FBS; Atlanta 
Biologics; Cat. # S11150) and 1% vol/vol antibiotic-antimycotic (Gemini Bio-Products; 
Cat. # 400-101). 
Osteoinductive media was prepared from the aforementioned α-MEM and further 
supplemented with 50 mg/L of L-ascorbic acid (Sigma; Ref. # A4544), 10 mM β-
glycerophosphate (Sigma; Ref. # G5422), and 10 nM dexamethasone (Sigma; Ref. # 
D4902). 
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All media was prepared fresh at the start of each experiment and discarded immediately 
upon reaching a pH outside of the range of 7.2 – 7.4 or after one month of storage at 4 
°C. 
 
2.1.3 Cell Culture and Expansion 
All cells were kept in an incubator set to 37 °C, 95% relative humidity, and 
supplemented with 5% CO2. Up until such point as cells were seeded into a bioreactor, 
their media (only basal α-MEM was used during cell culture and expansion) was 
changed every Monday, Wednesday, and Friday until they reached a maximum of 80% 
confluency within a T-75 cell culture flask (Corning; Ref. # 430641U) (with the 
exception of the immediate post-extraction cell culture deviation as described in 
Section 2.1.1). Upon achieving 70 – 80% confluency, cells were passaged. Cells were 
first lifted from their flasks by removing the media from each flask, rinsing the flasks 
with 5 mL of Dulbecco’s phosphate buffered saline (PBS; gibco; Ref. # 21600-010), 
removing the PBS, incubating the flask with 1 mL of Trypsin-EDTA (Sigma; Ref. # 
T4049), and removing the cells with excess α-MEM into a conical tube. This tube was 
then centrifuged at 1100 rcf for 5 min to pelletize the cells. The supernatant (containing 
α-MEM and trypsin) was removed, the cell pellet was homogenized into fresh α-MEM 
and subsequently fed into sterile T-75 flasks at a concentration of 250,000 – 333,000 
cells per flask. Each flask was then brought to a total of 10 mL with fresh α-MEM. 
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2.1.4 Scaffolds 
The scaffold utilized within these experiments were approximately 85% porous 
spunbonded poly(l-lactic acid) (PLLA; grade 6251D, 1.4% D-enantiomer, MW = 
108,500, PDI = 1.87, NatureWorks LLC.) meshes approximately 5 mm in height and 8 
mm in diameter.  
Scaffolds were produced via the spunbonding process due to its many benefits. It is a 
simple, single unit operation amenable to fiber formation of myriad polymers in 
addition to being easily implementable from lab scale to full industrial scale processes 
84–86. Furthermore, the resulting highly porous scaffolds have immensely-interconnected 
pores. The spunbonding process consists of forcing molten polymer through a die and 
subsequently attenuating the resulting fiber by rapidly drawing it through an air venturi.  
The equipment setup was the same as that used in previous studies in the lab; consisting 
of a Brabender™ single screw extruder (19.1 mm diameter, 381 mm length, 
compression ratio of 3:1, maintained at 265 °C), a spin pack equipped with a Zenith™ 
gear pump (maintained at 275 °C), and a spinneret (0.42 mm inner diameter, 2.97 mm 
length, maintained at 280 °C). 100 cm below the spinneret, the fiber was attenuated in 
an air venturi 84. A screen approximately 150 cm below the venturi was used to 
manually collect the attenuated fiber into random nonwoven layers. A diagram of this 
setup is provided in Figure 10a, below. Several sheets were stacked to obtain sheets of 
approximately 0.055 g / cm2. These sheets were subsequently compressed to obtain a 
thickness of approximately 5 mm. The resulting porosity was determined to be 
approximately 85%, with fiber diameters of approximately 20 µm, and pores of 
approximately 250 µm in diameter (µCT images of the scaffold architecture are 
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provided in Figure 10b, below). Cylindrical plugs 8 mm in diameter were punched 
from these sheets to produce the final scaffolds for use in the bioreactor setup. 
 
Figure 10. Spunbonding Process and Scaffolds 
A diagram of the spunbonding process details the principle components (a., 
copied from 87). SEM images of the spunbonded scaffolds used in the 
experiments conducted herein are provided at two different magnifications (b.). 
 
2.1.5 Flow Perfusion Bioreactor System 
The bioreactor system utilized for these experiments was based on the design by 
Bancroft, Sikavitsas, and Mikos 88. The system comprises a main body connected with a 
reservoir system by tubing and a peristaltic pump. The body is composed of an acrylic 
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block approximately 1.5” in thickness containing six individual hollowed-out chambers 
allowing for one sample each. Into these chambers are placed cassettes with O-rings at 
the top and bottom of each. A scaffold is press-fit into each cassette to ensure snug, 
immovable positioning, requiring media flow to perfuse directly through the scaffold. A 
threaded top provides the means to seal each cassette into a chamber. Tubing adapters 
located at the top of each threaded top and the bottom of each chamber provide the 
means for attachment of 1/16” ID tubing (Cole-Parmer; Item# EW-96410-13). This 
tubing was selected as it is permeable to both O2 and CO2, allowing for both the re-
oxygenation of media from the exit of each chamber until its re-entry and the 
facilitation of the buffering effect CO2 has on the circulating media. Upon exiting the 
chambers, tubing directs the flow of media into one reservoir of a dual reservoir system. 
This effluent reservoir is attached to the feed reservoir by a small length of tubing 
connecting hollow glass barbs at the bottom of each reservoir. This provides the means 
for media recirculation, wherein the effluent media flows back into the feed reservoir 
before being fed via peristaltic pump (Langer Instruments; Model # BT100-1L) back 
into each scaffold chamber. It is important to note that each scaffold chamber has its 
own feed and effluent tubing (for a total of 12 tubing segments per bioreactor), all of 
which feed from (and deposit into) the globally-shared media reservoir system. 
Additionally, the system was equipped with oxygen sensing modules (see Section 2.2.1 
for details) placed immediately before and after each individual scaffold chamber. 
Figure 11, below, details the major components of the system. 
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Figure 11. Key Components of Flow Perfusion Bioreactor System 
The bioreactor system comprises an acrylic body (a.) which houses the reactor 
assemblies (c. and d.), a reservoir system (b.), oxygen permeable tubing (not depicted), 
and a peristaltic pump (not depicted). The body (a.) contains six individual chambers to 
allow for continuous culture of up to six constructs. The dual-bottle reservoir system 
(b.) allows for continuous recirculation of media throughout the bioreactor while further 
allowing for easy changing of media and quantification of flow rate. The reactor 
assemblies (provided in both an exploded and assembled view, c. and d., respectively) 
allow for the immobilization of, and forced media perfusion through, cultured 
constructs. These assemblies consist of two barbed tubing adapters (green), a threaded 
compression top (blue), and a cassette (red with black O-rings) into which a scaffold is 
placed, all housed within the reactor body (gray). 
 
2.1.6 Pre-Seeding Scaffold Treatments 
Prior to seeding, full liquid intrusion of the scaffolds was facilitated via a pre-wetting 
procedure 89. Ensuring full liquid intrusion allows for more homogenous cellular 
intrusion into the scaffold and overall increased seeding efficiency 89. The procedure 
consisted of submerging the scaffolds in 95% ethanol (due to its lower surface-tension 
than water) in a septum-sealed beaker and manually pulling a vacuum on the contents of 
From Chamber To Chamber 
Tubing from  
Feed Reservoir 
Tubing to  
Effluent Reservoir 
a. 
b. c. d. 
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the beaker with a syringe. The low pressure environment produced by this method 
forces air contained within the scaffold to be displaced by the ethanol as observed by 
vapor bubble formation within and dissipation from the scaffolds. Vacuum was 
continuously pulled until such time as no more bubble evolution was observed. Next, 
the vacuum was released and the scaffolds were transferred to a beaker of PBS for a 
minimum of 30 minutes in order to displace the otherwise cytotoxic ethanol. 
After pre-wetting, scaffolds were press-fit into cassettes which were then placed within 
the bioreactor chamber before closing the system. The pump was then turned on to 
allow media to circulate throughout the system and perfuse through the scaffold for a 
minimum of 1 hour prior to seeding. The reasons for this are two-fold: first to ensure 
there are no leaks within the system, and second to allow for protein attachment to the 
scaffold to facilitate cell attachment during seeding. 
 
2.1.7 Dynamic Seeding 
Scaffolds were dynamically seeded to promote better cell dispersion and homogeneity 
throughout the construct. This was accomplished by pipetting 150 µL of a cell 
suspension containing the desired concentration of cells (~2MM cells/150 µL) dispersed 
in α-MEM directly on top of the scaffold, closing the system, and beginning an 
oscillatory flow regimen. This regimen consisted of perfusing media through the 
scaffolds at a rate of 0.15 mL/min/scaffold in alternating directions with a period of one 
minute (i.e. one minute in forward, one minute in reverse, etc.) for one hour. After this 
oscillatory flow regimen, the flow was stopped, and the cells were allowed to attach to 
the scaffolds during a rest period of two hours. The flow was turned on in the forward 
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direction for the remainder of the experiment. Immediately following this rest phase, the 
entire volume of media within the system was replaced with fresh media (either 
osteoinductive media or α-MEM, depending on the group) in order to remove all 
unattached cells and prevent their accumulation elsewhere in the system. A diagram of 
this process is provided below, in Figure 12.  
 
 
Figure 12. Dynamic Seeding Process 
Scaffolds (having been pre-treated as described in Section 2.1.6) were seeded by first 
pipetting 2MM rMSCs onto each scaffold followed by one hour of oscillatory flow 
wherein media was perfused through each in alternating directions at a flowrate of 150 
µL/min with a period of oscillation equal to one minute. This oscillatory (or dynamic) 
seeding regimen is utilized to produce a more homogenous distribution of cells 
throughout each scaffold (as demonstrated in the figure). After dynamic seeding, flow is 
then turned off for two hours to allow for cell attachment. 
 
2.1.8 Replacing Media in Bioreactor System 
The entire volume of media within the reactor was replaced every two or three days. 
This was accomplished by turning off the pump, suctioning out the entire volume of 
media contained within both reservoirs, clamping the segment of tubing between the 
reservoirs, filling the feed reservoir with the desired content of the desired media (set as 
Pre-Treated 
Scaffold 
Statically-Seeded 
Construct 
Dynamically-
Seeded Construct 
2MM rMSCs in 150 
µL suspension 
pipetted onto 
scaffold 
1 hr oscillatory seeding regimen  
(flowrate = 150 µL/min, 
period of oscillation = 1 min) 
38 
16.67 mL per active construct), turning the pump back on in the forward direction and 
allowing the system to run thusly for 20 minutes (calculated as the time required for the 
media within the feed reservoir to reach the effluent reservoir), removing the media 
accumulated in the effluent reservoir (as this was the old media still remaining in the 
tubing), removing the clamp between the reservoirs and returning the bioreactor to the 
incubator. Prior to being disposed of, the media accumulated in the effluent reservoir 
was measured, allowing for the calculation (and if required, recalibration) of the media 
flowrate through the system. 
 
2.2 Species Measurement Methods 
The numerous species investigated within this experiment were measured via various 
means. Some species were measured from construct samples (after sacrifice of said 
constructs) as a direct means for determination of certain properties (such as cellularity, 
mineralization, degree of differentiation, etc.) of the constructs following established 
methods. Constructs were sacrificed by removing them from their cassettes, tearing 
them apart into small segments, and placing said segments in 1 mL if nanopure water.  
Other species were measured from global media samples (taken immediately prior to 
each media change and frozen at -20 °C) as the basis for the establishment of an indirect 
means for the determination of such properties. As such, some of the quantified species 
provide construct-specific values while others are global values. Each species and the 
method of its measurement is discussed further below. 
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2.2.1 Oxygen 
The dissolved oxygen content of the media was measured at the entrance to and exit 
from each individual construct-containing chamber of the bioreactor. It is important to 
note that the tubing used throughout the majority of the system was permeable to 
oxygen, and that a sufficient length of tubing was used such that full re-oxygenation of 
the media was achieved between the time it exited the scaffold-chamber and the time it 
re-entered a scaffold-chamber. Measurements were obtained with an optical dissolved 
oxygen probe system. The system used was a NeoFox Kit with RedEye® oxygen 
sensing patches, a system which measures the concentration of molecular oxygen 
without consuming it (Ocean Optics). RedEye® patches were affixed to the interior of 
custom-build oxygen sensing modules (referred to henceforth as OxyMods) which were 
then placed in line with the construct chambers, both before and after the chambers. A 
small segment of non-oxygen-permeable tubing was used to attach each OxyMod to the 
barbed tubing adapters on the bioreactor body (to prevent re-oxygenation of media 
between the measurement locations). Figure 13, below, shows the key components of 
the NeoFox system and the custom-built OxyMods. 
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The NeoFox Kit (a.) contains a phase fluorimeter, bifurcated fiber probe, thermistor 
probe, RedEye® patches, and NeoFow Viewer software. The RedEye® patches were 
affixed to the inside of custom-made OxyMods as seen in b. 
 
The RedEye® patches contain a proprietary formulation of fluorescent organometallic 
molecules; the fluorescence of these molecules is quenched in the presence of O2, 
proving the means for detection and quantification thereof. The system operates by 
emitting a blue light (as a 10 Hz pulsating square wave) through a fiber optic cable with 
a probe adapter which is held up to the patch; this blue light excites the fluorescent 
complex which then emits a responsive signal (of red light) which is subsequently read 
by a detector. The detector tracks the fluorescent decay profile, which is a function of 
the concentration of molecular oxygen. The signal from the detector is then analyzed by 
the NeoFox Viewer software package. It utilizes a Stern-Volmer equation to calculate 
the oxygen content as a function of the fluorescent decay as follows 90: 
 
 
 Non-O2-Permeable 
Tubing 
Square Glass Tubing 
with RedEye® Patch 
Inside 
Glass Tubing Reducer 
Glass Tubing Reducer 
O2-Permeable Tubing 
a. b. 
Figure 13. NeoFox System and OxyMods 
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𝐹0
𝐹
=
𝜏0
𝜏
= 1 + 𝑘𝑞 ∗ 𝜏0 ∗ [𝑂2] = 1 + 𝐾𝑆𝑉 ∗ [𝑂2] (Eqn. 1) 
 Where 𝐹0 = fluorescent intensity in absence of O2 
  𝐹 = fluorescent intensity in presence of O2 
  𝜏0 = fluorescent decay time in absence of O2 
  𝜏 = fluorescent decay time in presence of O2 
  𝑘𝑞 = bimolecular quenching constant 
  𝐾𝑆𝑉 = Stern-Volmer constant for static decay 
  [𝑂2] = concentration of molecular oxygen present at fluorophore 
 
The RedEye® patches were supplied with pre-calibration files wherein the above 
constants were calculated over the entire operating temperature range (as they do vary 
with temperature). Initial calibration adjustments were performed prior to each 
bioreactor setup by using a single-point offset wherein pure water at 25 °C was set to 
8.2 ppm. This built-in re-calibration method shifts all of the calculated values to correct 
for the signal loss through the glass. The effect of salinity on these readings was 
determined to be negligible, resulting in a less than 1% aberration from the uncorrected 
values. As the reading for each individual patch could vary slightly, at the start of each 
bioreactor setup initial pre-seeding oxygen measurements for each OxyMod were 
recorded to correct for these variations.  
Oxygen measurements were obtained prior to each media change and/or construct 
sacrifice. Read values were allowed to level-off (after approximately 10 seconds of 
holding the probe in line with the RedEye® patch within an OxyMod) prior to 
recording values. 
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2.2.2 Glucose 
Measurements of glucose were made on global media samples utilizing a GlucCell™ 
Glucose Monitoring System (CESCO BioProducts; Ref. # DG1000, Figure 14, below). 
This meter, though proprietary, most likely utilizes an enzymatic glucose oxidase 
reaction wherein glucose oxidase immobilized on test strips converts glucose in a 
sample to gluconic acid and hydrogen peroxide 91. The hydrogen peroxide is then 
oxidized, releasing two electrons; the release of these electrons induces a current which 
is read by the sensor and converted (via internal calibrations) to a glucose concentration 
readout 91. 
This meter has a test range of 1.6 – 33.3 mM, well beyond the 3.0 – 5.7 mM range for 
sample measurements. Samples were thawed and vortexed to ensure homogeneity. A 10 
µL volume was suspended from a pipette tip then touched to the sample port on a new 
GlucCell™ test strip, allowing it to be pulled into the reaction chamber. All samples 
were run in triplicate. 
 
Figure 14. GlucCellTM Glucose Monitoring System 92 
Glucose measurements were obtained with the GlucCell™ (CESCO 
BioProducts). The device is depicted along with two vails of test strips, 
three individual test strips, and a device tester. 
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2.2.3 Osteoprotegerin 
Measurements of osteoprotegerin (OPG) were made on global media samples utilizing 
an enzyme-linked immunosorbent assay kit (ELISA; LifeSpan Biosciences, Inc.; Ref. # 
LS-F12843). The detection range of this assay is 15.6 – 1000 pg/mL. 
This kit utilizes the sandwich ELISA principle wherein a sample is added to a 96-well 
plate coated with an immobilized capture antibody (in this case an anti-rat OPG 
antibody) to which the analyte of interest attaches (in this case, rat OPG). After washing 
the plate to remove unbound species, a biotinylated detection antibody (also anti-rat 
OPG) is added in solution to bind to the bound analyte of interest. Next, after a wash 
step, a solution of streptavidin-horseradish peroxidase enzyme complex is added, which 
then attaches to the biotin of any bound detection antibody. Then, after a wash step, a 
solution of 3,3′,5,5′-Tetramethylbenzidine (TMB) is added; this chromogenic substrate 
is oxidized by the HRP, turning the solution into a blue color. After a specific amount of 
time, the reaction is stopped with the addition of a sulfuric acid, which disrupts the 
enzyme and changes the solution to a yellow color, readable at 450 nm. A brief 
schematic of these steps is provided in Figure 15, below. 
Running standards along with the samples of unknown concentration allows for the 
quantification of the analyte in these samples. Standard curves were fit to a sigmoidal 4-
parameter logistic curve for proper determination of sample analyte concentrations. All 
samples and standards were run in duplicate per kit recommendation. 
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Figure 15. Pictographical representation of the sandwich ELISA principle [4] 
A plate coated in the appropriate capture antibody (in this case anti-rat OPG) captures 
the target analyte present in a sample. To this bound analyte a second, biotinylated 
detect antibody (again, anti-rat OPG) subsequently binds. Next, streptavidin-conjugated 
horseradish peroxidase (HRP) is added, which binds to the biotin presenting on the 
detect antibody. Then, 3,3′,5,5′-Tetramethylbenzidine (TMB) is oxidized by the HRP to 
3,3',5,5'-tetramethylbenzidine diimine (at a rate proportional to the concentration of the 
target antigen (rat OPG) present in the original sample). Finally, this reaction is stopped 
by the addition of sulfuric acid, and the plate is read at an absorbance wavelength of 
450 nm. 
 
2.2.4 Osteocalcin 
Measurements of osteocalcin (OCN) were made on global media samples utilizing an 
enzyme-linked immunosorbent assay kit (ELISA; LifeSpan Biosciences, Inc.; Ref. # 
LS-F12230). The detection range of this assay is 62 – 4000 pg/mL. This kit utilizes the 
sandwich ELISA principle, see Section 2.2.3, above, for explanation. All samples and 
standards were run in duplicate per kit recommendation. 
 
2.2.5 Cellularity (via dsDNA Quantification) 
Measurements of double-stranded DNA (dsDNA) were made on the solution of 
constructs immersed in 1 mL of nanopure water and subjected to three freeze-thaw 
cycles wherein the constructs were sequentially frozen solid at -20 °C, thawed at 25 °C, 
and vortexed for 5 seconds prior to re-freezing. The resulting cell lysate was assayed for 
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dsDNA content utilizing a Quant-iT™ PicoGreen® dsDNA assay kit (Invitrogen; Cat. # 
P11496). The PicoGreen® reagent binds specifically to double-stranded DNA, 
providing the means for quantification. Standards over the range of the assay (0.1 – 3.0 
µg/mL) were prepared with λ-DNA. 43 µL aliquots of all samples and standards were 
added to 257 µL of reaction mixture (10 mM Tris-HCl, 1 mM EDTA, 1.3 µL 
PicoGreen® reagent, pH 7.5) in an opaque 96-well plate and allowed to incubate for 5 
min. The plate was then read on a Synergy HT microplate reader (Bio-Tek) for 
fluorescence with an excitation wavelength of 490 nm and an emission wavelength of 
520 nm. The resulting intensity values were used along with the standard curve to 
quantify the concentration and ultimately content of dsDNA per sample. All samples 
and standards were run in triplicate. 
The dsDNA content was then divided by the known dsDNA content per cell as obtained 
by performing the same assay on known quantities of cells cultured concurrently in T75 
cell culture flasks and sacrificed at various time points (and counted prior to assay with 
a hemocytometer). NOTE: the dsDNA content of the cells was found to vary with time 
as the immature rMSCs differentiated into mature osteoblasts. This time-variable 
dsDNA content was used in the determination of cellularity, and is discussed further in 
the Section 3.1.1. 
 
2.2.6 Alkaline Phosphatase Activity  
Measurements of alkaline phosphatase (ALP) activity were made on the same cell 
lysate solution as that used for quantification of cellularity described above. These 
measurements were performed utilizing a fluorometric assay based on the enzymatic 
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conversion of p-nitrophenol phosphate (pNPP) to p-nitrophenol (pNP). Standards of 
pNP were prepared over the range of the assay (0 – 200 µM). 80 µL aliquots of each 
sample and standard were added to 20 µL of glycine buffer (0.1 M glycine, 1 mM 
MgCl2, 1 mM ZnCl2, pH 10.4) and 100 µL of substrate solution (1 mg/mL pNPP in 
glycine buffer) in a clear 96-well plate and allowed to incubate at 37 °C for 30 min 
before being stopped with the addition of 50 µL of stop solution (3.0 M NaOH). The 
plate was then read on a Synergy HT microplate reader (Bio-Tek) at an absorbance 
wavelength of 410 nm. The resulting absorbance values were used along with the 
standard curve to quantify the concentration of reacted pNPP and ultimately the activity 
of ALP in each sample. All samples and standards were run in triplicate. 
 
2.2.7 Calcium 
Measurements of calcium deposition were made on the same cell lysate solution as that 
used for quantification of cellularity and ALP activity described above after said assays 
were performed. The remaining cell lysate was diluted 1:1 with 1 M acetic acid and 
agitated overnight to solubilize deposited calcium. The resulting solution was then 
assayed for calcium content utilizing a calcium colorimetric assay (Sigma, Cat. # 
MAK022). Standards were prepared from CaCl2 over the range of the assay (0 – 200 
µg/mL). 10 µL aliquots of each sample and standard were added to 100 µL of buffer 
solution (500 mM 2-amino-2-methyl-1,3 propanediol) and 100 µL of binding reagent 
(o-cresolphtalein Complexone® and 0.024% 8-hydroxyquinoline) in a clear 96-well 
plate. The plate was then read on a Synergy HT microplate reader (Bio-Tek) at an 
absorbance wavelength of 575 nm. The resulting absorbance values were used along 
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with the standard curve to quantify the concentration and ultimately content of calcium 
in each sample. All samples and standards were run in triplicate. 
 
2.3 Species Rate of Change Calculations 
The aforementioned species concentrations were measured on samples obtained at 
specified (recorded) times. As such, the rate of change of each species was able to be 
calculated. The only exception to this is that for the concentration oxygen, whose rate of 
change is a direct function of flowrate (and an indirect function of time).  
 
2.3.1 Oxygen Uptake Rate 
A flowrate-dependent open-system mass balance on O2 across each construct was 
derived to be: 
 
𝑑𝐶𝑂2
𝑑𝜏
∗ 𝑉𝑐ℎ ∗ 𝜖 = 𝑂𝑈𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 = 𝑁𝑐𝑒𝑙𝑙𝑠 ∗ 𝑞𝑂2 (Eqn. 2a) 
Or, assuming zero-order kinetics for 𝑞𝑂2: 
 (𝐶𝑂2,𝑜𝑢𝑡 − 𝐶𝑂2,𝑖𝑛) ∗ 𝜈 = 𝑂𝑈𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 (Eqn. 2b) 
 = 𝑁𝑐𝑒𝑙𝑙𝑠 ∗ 𝑞𝑂2 (Eqn. 2c) 
 Where 𝐶𝑂2 = concentration of O2 (subscripts “in” and “out” correspond 
   to inlet and outlet of construct, respectively) 
  𝜏 = residence time = 𝑉𝑐ℎ ∗ 𝜖/𝜈  
  𝑉𝑐ℎ = volume of chamber 
  𝜖 = porosity of construct 
  𝜈 = volumetric flow rate of media through construct 
  𝑂𝑈𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 = construct oxygen uptake rate 
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  𝑁𝑐𝑒𝑙𝑙𝑠 = number of cells within each construct 
  𝑞𝑂2 = cell-specific oxygen uptake rate 
 
Utilizing these equations, 𝑂𝑈𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 can be directly calculated in real-time during in 
vitro culture. If 𝑞𝑂2 (which may be a non-zero-order function of 𝐶𝑂2, in particular 
observing Michaelis-Menten kinetics) is known, then 𝑁𝑐𝑒𝑙𝑙𝑠 can be directly calculated as 
well. 𝑞𝑂2, however, is seen to be a function of more than just 𝐶𝑂2, varying also with the 
degree of differentiation of the cells within the construct. 
 
2.3.2 Glucose Consumption Rate 
Due to the low cell-specific glucose consumption rate, a measurable decrease across 
each construct (as a function of flowrate) is not obtainable. As such, glucose 
consumption rates were measured as functions of time. Furthermore, due to the global 
media circulation system, all rates calculated from circulating media values are global-
average values. Therefore, a global time-dependent closed-system mass balance on 
glucose was derived to be: 
 
𝑑𝐶𝑔𝑙𝑐
𝑑𝑡
= −
𝑁𝑐𝑒𝑙𝑙𝑠∗𝑁𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑠∗𝑞𝑔𝑙𝑐
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 3a) 
Or, assuming zero-order kinetics for 𝑞𝑔𝑙𝑢𝑐𝑜𝑠𝑒: 
 
[𝐶𝑔𝑙𝑐,0−𝐶glc,Δ𝑡]
Δ𝑡
=
𝐺𝐶𝑅𝑔𝑙𝑜𝑏𝑎𝑙
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 3b) 
 =
𝑁𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑠∗𝐺𝐶𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 3c) 
 =
𝑁𝑐𝑒𝑙𝑙𝑠∗𝑁𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑠∗𝑞𝑔𝑙𝑐
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 3d) 
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 Where 𝐶𝑔𝑙𝑐 = concentration of glucose (subscripts “0” and “Δt”  
   correspond to time of media change and time of media 
   sample, respectively) 
  𝑁𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑠 = number of active constructs in bioreactor system 
  𝑞𝑔𝑙𝑐 = cell-specific glucose consumption rate 
  𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡 = total volume of media in bioreactor over time Δt 
  𝐺𝐶𝑅𝑔𝑙𝑜𝑏𝑎𝑙 = global glucose consumption rate 
   𝐺𝐶𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 = construct glucose consumption rate 
 
Utilizing these equation, 𝐺𝐶𝑅𝑔𝑙𝑜𝑏𝑎𝑙 and 𝐺𝐶𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 can be directly calculated in real-
time during in vitro culture. If 𝑞𝑔𝑙𝑐 (which may be a non-zero-order function of 𝐶𝑔𝑙𝑐, in 
particular observing Michaelis-Menten kinetics) is known, then 𝑁𝑐𝑒𝑙𝑙𝑠 can be directly 
calculated as well. Similarly to oxygen, 𝑞𝑔𝑙𝑐 is seen to vary with the degree of 
differentiation of the cells within the construct, further complicating the analysis. 
 
2.3.3 Osteoprotegerin Production Rate 
The global time-dependent closed-system mass balance on osteoprotegerin is of the 
same form of that derived for glucose, Eqn. 14a (above), with the elimination of the “-“ 
sign (as OPG is being produced, not consumed), such that: 
 
𝑑𝐶𝑂𝑃𝐺
𝑑𝑡
=
𝑁𝑐𝑒𝑙𝑙𝑠∗𝑁𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑠∗𝑞𝑂𝑃𝐺
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 4a) 
Again, assuming zero-order kinetics: 
 
[𝐶𝑂𝑃𝐺,Δ𝑡−𝐶OPG,0]
Δ𝑡
=
𝑂𝑃𝐺𝑃𝑅𝑔𝑙𝑜𝑏𝑎𝑙
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 4b) 
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 =
𝑁𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑠∗𝑂𝑃𝐺𝑃𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 4c) 
 =
𝑁𝑐𝑒𝑙𝑙𝑠∗𝑁𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑠∗𝑞𝑂𝑃𝐺
𝑉𝑚𝑒𝑑𝑖𝑎,𝑡𝑜𝑡
 (Eqn. 4d) 
 Where 𝐶𝑂𝑃𝐺 = concentration of OPG (subscripts “0” and “Δt”  
   correspond to time of media change and time of media 
   sample, respectively) 
  𝑞𝑂𝑃𝐺 = cell-specific OPG production rate 
  𝑂𝑃𝐺𝑃𝑅𝑔𝑙𝑜𝑏𝑎𝑙 = global OPG production rate 
   𝑂𝑃𝐺𝑃𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 = construct OPG production rate 
Similarly to oxygen and glucose, 𝑂𝑃𝐺𝑃𝑅𝑔𝑙𝑜𝑏𝑎𝑙 and 𝑂𝑃𝐺𝑃𝑅𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡 can be calculated 
directly in real-time during in vitro culture. Furthermore, 𝑞𝑂𝑃𝐺 is also seen to vary with 
the degree of differentiation of the cells within the construct. 
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3. RESULTS AND DISCUSSION 
 
3.1 Post-Culture Construct Analyses 
Although it might seem more appropriate to discuss the mid-culture analyses prior to 
discussion of the post-culture ones, the former data has no real significance without the 
latter. Overcoming this hurdle is indeed the purpose of the project herein, granting 
significance to these mid-culture analyses, circumventing the need to perform post-
culture destructive analyses altogether. 
 
3.1.1 Construct Cellularity Analysis 
The first aspect of a construct determined via destructive, post-culture analysis was for 
cellularity (to ensure that cells were indeed present on the construct, and quantify their 
numbers for use in other analyses). As a dsDNA assay was used for this purpose, first 
the dsDNA content of each cell had to be determined. The resulting analysis showed 
this content to start at approximately 4.5 pg/cell for immature MSCs and steadily 
decrease to a value of approximately 2.5 pg/cell by day 14 for MSCs differentiating into 
osteoblasts. Over this time range (from day 0 to day 14), the cellularity of MSCs 
cultured in non-osteoinductive α-MEM was set at 4.5 pg/cell, while for differentiating 
MSCs the dsDNA content was calculated according to Equation 5 as determined from 
experimental data (not shown). 
 𝑚𝑑𝑠𝐷𝑁𝐴
𝑐𝑒𝑙𝑙
(𝑝𝑔) = 4.5 − 0.0102 ∗ 𝑡2 (Eqn. 5) 
 Where 𝑡 = culture time (in days) 
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This diminution in cellular dsDNA content can be attributed to the loss of proliferative 
ability by osteoblasts as compared with their progenitor MSCs. The resulting cellularity 
profiles for both the osteo-induced and non-osteoinduced reactors are provided in 
Figures 16 and 17, below (the difference between the two figures being the elimination 
of the Day 0 data points from both data sets, allowing for easier reading of later data 
points). Note: Day 0 refers to the amount of cells initially dispensed on top of each 
scaffold prior to initiation of the oscillatory seeding regimen.  
 
Figure 16. Construct Cellularity Day 0 – 14 
The cellularity of the two data sets (osteoinduced constructs, “Osteo,” in dark gray, non-
osteoinduced, “MEM,” in light gray) is seen to decrease and steady-off. The large 
decrease from Day 0 to Day 1 is typical, as Day 0 is the number of cells dispensed onto 
each construct prior to seeding, and Day 1 is the cellularity after one day being 
subjected to flow perfusion. The ratio of Day 1 to Day 0 is seeding efficiency, being 
49% and 34% for the osteo- and non-osteo-induced constructs, respectively. Further 
analysis of the remaining data points available in Figure 17, below. Values are 
presented as mean ± SEM (N=4 for Osteo, 3 for MEM). Significance calculated via 
ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p < 0.05. 
 
 
 
 
* 
* 
* 
* 
* * * * 
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Figure 17. Construct Cellularity Day 1 – 14 
The cellularity of the Osteo group is seen to level off to approximately 320,000 cells per 
construct by Day 5, while the MEM group levelled off to a much lower 40,000. This 
could potentially be due to increased binding affinity of the cells as they differentiate 
from MSCs (typically found in suspension within marrow in vivo) to osteoblasts 
(typically bound to osteoid in vivo). Values are presented as mean ± SEM (N=4 for 
Osteo, 3 for MEM). Significance calculated via ANOVA with Tukey HSD Post-hoc 
analysis, “*” signifies p < 0.05. 
 
From the figures above, it is evident that the cellularity of the constructs levels off by 
Day 5, remaining fairly constant for the remainder of the experiment. Furthermore, it 
can be seen that the Osteo constructs maintained a significantly higher cellularity than 
the MEM ones. It is hypothesized that this is due to a potential higher affinity for 
attachment by osteoblastic-differentiating MSCs based on the fact that MSCs are 
typically found in solution in vivo within red bone marrow, being recruited and 
attaching to defect sites in the first step of their osteoinduction. It is important to note 
here, again, that both groups were seeded with non-osteoinductive media which was 
changed immediately after the seeding protocol with the respective media for each 
group. 
* 
* 
* 
* 
* 
* 
54 
3.1.2 Alkaline Phosphatase Activity Analysis 
As has been mentioned previously, alkaline phosphatase (ALP) exhibits increased 
production in osteoblasts due to its importance in mineral deposition. As such, it is often 
used as an indicator of osteoblastic differentiation, as it is used herein. The figures 
below reveal the ALP activity per construct (Figure 18), and per cell (Figure 19).  
 
Figure 18. ALP Activity per Construct Day 1 – 14 
A baseline level of ALP is seen to be expressed within the immature constructs as 
evinced by steady expression through Day 5. The activity level of alkaline phosphatase 
within each construct is seen to increase markedly between Days 7 and 9 for the Osteo 
group while remaining low in the MEM group. Values are presented as mean ± SEM 
(N=4 for Osteo, 3 for MEM). Significance calculated via ANOVA with Tukey HSD 
Post-hoc analysis, “*” signifies p < 0.05. 
 
Due to the significant differences in cellularity between the two groups, a more apt 
analysis is provided by Figure 19, giving the ALP activity per cell. Nonetheless, both 
graphs demonstrate a significant increase in ALP activity from Day 7 to Day 9 for the 
Osteo group and no significant change for the MEM group. This observation serves as a 
primary indication of osteoblastic differentiation of the MSCs within the Osteo group, 
helping to validate that Objective 1 has been met. 
* 
* 
* * 
* 
* 
55 
 
Figure 19. ALP Activity per Cell Day 1 – 14 
A baseline level of ALP is seen to be expressed by immature MSCs as evinced by 
steady expression through Day 7. The activity level of alkaline phosphatase per cell is 
seen to increase markedly between Days 7 and 9 for the Osteo group while remaining at 
the baseline level in the MEM group. This result is a typical indication of osteoblastic 
differentiation. Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). 
Significance calculated via ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p 
< 0.05. 
 
3.1.3 Calcium Deposition Analysis 
Another key indicator of osteoblastic differentiation and bone formation is calcium 
deposition as secreting mineral (in the form of hydroxyapatite) is one of the main 
functions of osteoblasts. Figure 20, below, shows the calcium present within each 
construct over the culture period. A similar trend to that seen for ALP activity, above, is 
evident, with both groups exhibiting very low baseline levels of calcium (due to the 
presence of intracellular calcium), with a significant increase in calcium deposited from 
Day 7 to Day 9. Some of this difference can be explained by the differences in 
cellularity, though a majority of the difference is believed to be a result of the 
osteoinductive media differentiating the immature MSCs into osteoblasts. 
* 
* 
* 
* 
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Figure 20. Calcium Deposition Within Construct Day 1 – 14 
A low level of calcium is initially present within each scaffold, which can be attributed 
to intracellular calcium. A significant increase in calcium deposited within the construct 
between Day 7 and Day 9, a key indicator of osteoblastic differentiation and bone 
formation. Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). 
Significance calculated via ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p 
< 0.05. 
 
3.1.4 Summary of Post-Culture Analyses 
Overall, the above graphs exhibit several key trends. Firstly, the cellularity of constructs 
cultured in osteoinductive media are seen to have better cell attachment than those 
cultured in baseline non-osteoinductive media. Furthermore, the ALP activity and 
calcium deposition data support the conclusion that osteoinduced constructs 
demonstrate osteoblastic differentiation and “bone-like” formation as evinced by 
increases in both cell-specific ALP activity and total calcium deposited. These data 
support successful accomplishment of Objectives 1 and 3. 
 
 
 
* 
* * 
* 
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3.2 Mid-Culture Construct Monitoring 
During culture, oxygen reading and media samples for glucose and OPG assay allow for 
the real-time monitoring the OUR, GCR, and OPGPR. The values obtained, however, 
may only be calculated on a global or per-construct basis without prior knowledge of 
the cellularity of the construct. Having determined the cellularity of the constructs over 
time already, it is now possible to calculate cell-specific rates of oxygen and glucose 
uptake and OPG production (although, again, such determinations cannot currently be 
made without the destruction of constructs to determine their cellularity without the 
development of monitoring metrics, to be discussed in Section 3.4). 
 
3.2.1 Mid-Culture Oxygen Uptake Rates 
Oxygen measurements taken throughout the entire culture period allowed for the 
quantification of the oxygen uptake rate per construct in real-time (see Figure 21).  
 
Figure 21. Construct OUR Day 1 – 14 
The per-construct oxygen uptake rate (OUR) was calculated in real-time throughout the 
culture period. A fairly consistent (perhaps gradually increasing) OUR is observed for 
the Osteo group whereas a dramatic decline and leveling off is apparent for the MEM 
group. Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). 
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The construct-specific OUR alone does not allow for reliable determination of construct 
quality, being itself a function of cellularity and cell-specific oxygen uptake rate (both 
of which can change throughout the culture period). If, however, one of these two 
variables are known, the other can be calculated. As such, with the cellularity over time 
having been discussed previously, the data in Figure 21 can be divided by that in 
Figure 17 to determine the much more informative cell-specific oxygen uptake rate, 
𝑞𝑂2, over time presented in Figure 22, below. It is important also to note that 𝑞𝑂2 is in 
fact expected to be a function of local oxygen concentration wherein lower values 
would be expected for the same cell present in a less oxygen-rich environment. As such, 
due to the decreased oxygen availability towards the exit of the construct, it can be 
expected than minor decreases in 𝑞𝑂2 may be exhibited by cells present within these less 
oxygen-rich environments. This effect, however, was mitigated within this study as the 
minimum oxygen tension measured at the construct effluent for any of the groups was 
not less than 86% of saturation. Still, Figure 22 is presented as 𝑞𝑂2,𝑎𝑣𝑔, the average 
cell-specific oxygen uptake rate throughout the construct. 
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Figure 22. qO2 Day 1 – 14 
The average cell-specific oxygen uptake rate throughout the culture period was only 
able to be obtained after the destructive analysis of the construct to determine its 
cellularity. It can be seen that both groups start at the same 𝑞𝑂2,𝑎𝑣𝑔, followed by a fairly 
steady value of approximately 1.4 pmol O2/hr/cell for the MEM group and a potentially 
(though not significantly) increasing value up to a maximum at Day 14 of 2.4 pmol 
O2/hr/cell for the Osteo group. This lack of significance between the values is heavily 
attributed to the large error in the MEM values at later time points due to lower 
limitations of the oxygen probe to detect differences at low cellularities. Values are 
presented as mean ± SEM (N=4 for Osteo, 3 for MEM). 
 
The trends observed in Figure 22 suggest an increase in the cell-specific oxygen uptake 
rate of osteoblasts (~2.4 pmol/hr/cell) as compared with immature MSCs (~1.4 
pmol/hr/cell), a trend supported in the literature (see Section 1.2.6). Comparing the 
values obtained herein with literature values for the oxygen uptake rates of MSCs and 
osteoblasts, Pattappa et al. report a rate for human MSCs cultured under normoxia of 
~98-119 fmol/hr/cell for 44,45; Komarova et al. report values increasing from ~40 
fmol/hr/cell to ~200 fmol/hr/cell for differentiation to rat osteoblasts 93. It is important 
to note that these values were obtained for cells cultured on two-dimensional flasks, 
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providing a possible explanation for the approximately 10-20-fold higher oxygen uptake 
rates determined herein (cultured in 3D).  
 
3.2.2 Mid-Culture Glucose Consumption Rates 
Media samples obtained throughout the entire culture period allowed for the 
quantification of the glucose consumption rate per construct in real-time (Figure 23).  
 
Figure 23. Construct GCR Day 1 – 14 
The per-construct glucose consumption rate (GCR) was calculated in real-time 
throughout the culture period. Decreases over time are observed for both groups, with 
more dramatic declines for the MEM group. Values are presented as mean ± SEM (N=4 
for Osteo, 3 for MEM). 
 
As with the OUR, the construct-specific GCR alone does not allow for reliable 
determination of construct quality. As such, the cell-specific glucose consumption rate, 
𝑞𝑔𝑙𝑐, over time was calculated and is presented in Figure 24, below. Again, due to the 
decreasing glucose concentration throughout the culture period (between media 
changes), the values below are presented as 𝑞𝑔𝑙𝑐,𝑎𝑣𝑔, the average cell-specific glucose 
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consumption rate over the time period between media changes. As with 𝑞𝑂2,𝑎𝑣𝑔, the 
minimum glucose concentration (measured immediately prior to the change of media) 
was still fairly close to the starting concentration, at a maximum of an approximately 
20% decrease from the starting value. 
 
Figure 24. qglc Day 1 – 14 
The average cell-specific glucose consumption rate throughout the culture period was 
only able to be obtained after the destructive analysis of the construct to determine its 
cellularity. It can be seen that both groups start at the same 𝑞𝑔𝑙𝑐,𝑎𝑣𝑔, followed by a fairly 
steady value of approximately 1.0 pmol glucose/hr/cell for the MEM group and a 
potentially (though not significantly) decreasing value down to a minimum at Day 14 of 
0.4 pmol glucose/hr/cell for the Osteo group. This lack of significance between the 
values is heavily attributed to the large error in the MEM values at later time points due 
to accuracy limitations of the GlucCell™ meter to detect differences at low cellularities. 
Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). 
 
The trends observed in Figure 24 suggest a decrease in the cell-specific glucose 
consumption rate of osteoblasts (~0.4 pmol/hr/cell = 400 fmol/hr/cell)) as compared 
with immature MSCs (~1.0 pmol/hr/cell = 1000 fmol/hr/cell), a trend supported in the 
literature (see Section 1.2.6). Literature values for the cell-specific glucose 
consumption rate of MSCs are available: Pattappa et al. report values of ~360 
fmol/hr/cell and ~230 fmol/hr/cell for human MSCs 44,45; dos Santos et al. report values 
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of ~540 fmol/hr/cell for human MSCs 94; Schop et al. report values of ~250 fmol/hr/cell 
for rat MSCs 47. Although the values determined herein are approximately 2-4 fold 
higher than those reported in the literature, this is still within fairly good agreement. 
Again it is important to note that these literature values were obtained for MSCs 
cultured in two-dimensions whereas this experiment cultured them in three-dimensions, 
potentially accounting for the some of the difference. 
 
3.2.3 Mid-Culture OPG Production Rates 
Media samples obtained throughout the entire culture period allowed for the 
quantification of the OPG production rate per construct (Figure 25); although not 
analyzed in real time, methods could be developed to allow for real-time measurement 
of OPG levels present within circulating media.  
 
Figure 25. Construct OPGPR Day 1 – 14 
The per-construct OPG production rate (OPGPR) was calculated from media samples 
collected throughout the culture period. Similar trends are observed for both groups, 
with an initial decrease to a constant value, although significantly higher values are seen 
for the Osteo group as compared with the MEM group for all time points except Day 1. 
Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). Significance 
calculated via ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p < 0.05. 
* 
* 
* 
* 
* 
* 
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As with the OUR and GCR, a plot of the cell-specific OPG production rate was 
produced in order to better understand the quality of each construct; said plot is 
provided as Figure 26, below.  
 
Figure 26. qOPG Day 1 – 14 
The cell-specific OPG production rate throughout the culture period was only able to be 
obtained after the destructive analysis of the construct to determine its cellularity. Both 
groups start out with similar values, though this is followed by a large decline to 
minimal values (~0.1 fg OPG/hr/cell) for the MEM group whereas the Osteo group 
maintains a fairly steady rate of OPG production (~0.7 fg OPG/hr/cell).  Values are 
presented as mean ± SEM (N=4 for Osteo, 3 for MEM). Significance calculated via 
ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p < 0.05. 
 
The trends observed in Figure 26 suggest OPG secretion by osteo-induced MSCs is 
maintained at a steady value (at least through 14 days of culture) whereas non-osteo-
induced MSCs drastically decrease their production rates. Although no real literature 
values exist currently for OPG production rates by MSCs or osteoblasts, it is stated in 
the literature that MSCs express OPG constitutively, exhibiting increased expression 
through osteoblastic differentiation 28,29,95,96. It is important to note that OPG, as a 
regulatory signaling molecule, may exhibit drastically different expression profiles 
* 
* 
* 
* * 
* 
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under different conditions. As such, the values obtained herein may prove valid only for 
the specific system utilized herein. Furthermore, the intermittent changing of media, 
resulting in the removal of accumulated OPG may well have influenced its secretion, 
which may have been otherwise decreased under conditions of high concentration of 
circulating OPG. 
 
3.2.4 Mid-Culture Osteocalcin Detection 
Although only at very low levels, osteocalcin was detected in media samples collected 
on Days 11 and 14 for the osteoinduced cultures, with none being detected at any time 
point for the non-osteoinduced cultures. This timing corresponds well with the ALP 
activity and calcium deposition trends, as well as the observed divergences in oxygen 
uptake and glucose consumption rate for osteoinduced cultures as compared with non-
osteoinduced ones.  
 
3.2.5 Summary of Mid-Culture Analyses 
Overall, the graphs discussed above tend to suggest alterations in cellular oxygen 
uptake, glucose consumption, and OPG production rates as MSCs differentiate into 
osteoblasts. Decreasing glucose consumption along with concurrently increasing 
oxygen consumption suggests a shift in the metabolic profile from one more reliant on 
glycolysis to one benefiting more from oxidative phosphorylation, as supported by the 
literature (see Section 1.2.6). Furthermore, OPG production is seen to be maintained at 
a fairly constant level for the osteoinduced group while falling off rapidly for the non-
osteoinduced group. Finally, osteocalcin secretion is noticed in minimally-detectible 
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quantities only at late time points (Days 11 and 14) for osteoinduced cultures only. The 
elucidation of these trends partially fulfills Objective 2. Table 4, below, summarizes the 
cell-specific rates determined above alongside the literature. 
 
Calculated Values 
(Day 14) 
Literature 
Values 
Reference 
𝒒𝑶𝟐(fmol/hr/cell) 
MSC 1400 ± 600 
100 ± 20 
40 ± 10 
44 
93 
Osteoblast 2400 ± 300 200 ± 30 93 
𝒒𝒈𝒍𝒄(fmol/hr/cell) 
MSC 1000 ± 400 
540 ± 80 
250 ± 110 
94 
47 
Osteoblast 400 ± 100 - - 
𝒒𝑶𝑷𝑮(fg/hr/cell) 
MSC 0.1 ± 0.1 - - 
Osteoblast 0.7 ± 0.2 - - 
Table 4. Summary of Cell-Specific Rates 
Cell-specific rates calculated in this section compared with the literature (mean ± SD). 
Calculated values for MSC and osteoblast refer to Day 14 values for MEM and Osteo 
groups, respectively. 
 
It is important to note that while the above table presents singular values for each rate, 
these are more appropriately termed average values, with cells in culture perhaps 
exhibiting varied rates as functions of local concentrations. As explained earlier, due to 
gradients in oxygen concentration throughout the construct, along with predicted 
Michaelis-Menten kinetics for the rate of oxygen uptake, it is expected that cells near 
the end of the construct may exhibit a slightly lower 𝑞𝑂2 than those near the beginning, 
although the low decrease in oxygen across the constructs in the experiments presented 
herein should greatly reduce such variations. Similar effects should be noted for the 
rates of glucose consumption and OPG production, with changing concentrations over 
time perhaps altering their respective rates. Again, small decreases in global glucose 
concentration over the time interval between media changes should greatly reduce such 
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variations in 𝑞𝑔𝑙𝑐. In addressing these concerns, it is further important to note that the 
literature values referenced in Table 4 were obtained from 2D culture experiments 
which could have suffered from diffusional limitations and/or low local concentration 
effects, resulting in lower average values. This provides one possible explanation for the 
discrepancy between those rates calculated herein and those referenced in the literature. 
 
3.3 Development of Real-Time, Non-Destructive Quality Metrics 
As mentioned previously, the all-important cell-specific rates calculated in Section 3.3 
are not currently able to be obtained mid-culture without the sacrifice of a sample; 
however, these cell-specific rates can be used as key indicators of construct quality. 
Furthermore, such aspects as ALP production rate and calcium deposition (often used in 
the field as the principle means of determining the osteoblastic differentiation and 
formation of “bone-like” mineral within a construct) also require sample sacrifice to 
quantify. In order to overcome these ever-prevalent dilemmas (of not being able to 
determine a construct’s quality without destroying it), other metrics which allow for the 
determination of construct quality in real time without the need for sample sacrifice 
must be developed. Some promising alternatives will now be discussed. 
 
3.3.1 OUR, GCR, and OPGPR Ratios Throughout Culture Period 
The first logical step in developing such real-time, non-destructive metrics is the 
examination of ratios of the three mid-culture monitored molecules over time compared 
with the current destructive standards for determination of a bone tissue engineered 
construct’s quality: ALP activity and calcium deposition (Figures 19 and 20; Section 
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3.1). Implementing simple ratios of these potential marker molecules effectively negates 
the dependence on cellularity of each, resulting in functions which should be valid over 
vast ranges of cellularity (assuming negligible effect of cellularity on these values). 
Because there are three monitored molecules utilized herein, three independent plots 
can be produced via simple ratios of any two of these: these were determined to be 
OPGPR/GCR, OPGPR/OUR, and OUR/GCR (Figures 27 – 29, respectively). 
 
 
Figure 27. OPGPR/GCR Day 1 – 14 
The ratio of per-construct OPG production rate to glucose consumption rate throughout 
the culture period. Values are seen to increase slightly for the Osteo group, and decline 
for the MEM group, resulting in statistically significant values for all days but Day 1. 
Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). Significance 
calculated via ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p < 0.05. 
 
* 
* 
* 
* 
* 
* 
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Figure 28. OPGPR/OUR Day 1 – 14 
The ratio of per-construct OPG production rate to oxygen uptake rate throughout the 
culture period. Values are seen to increase decrease for both groups to steady values, 
though to a steady value much higher for the Osteo group than for the MEM group, 
resulting in statistically significant values throughout the culture period except for Day 
1. Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). Significance 
calculated via ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p < 0.05. 
 
Figure 29. OUR/GCR Day 1 – 14 
The ratio of per-construct oxygen uptake rate to glucose consumption rate throughout 
the culture period. Values for the MEM group are seen to remain fairly constant 
whereas those for the Osteo group tend to trend upward with time (on average). More 
marked differences between the two groups are seen for the later time points past Day 9. 
Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). Significance 
calculated via ANOVA with Tukey HSD Post-hoc analysis, “*” signifies p < 0.05. 
* 
* 
* 
* * * 
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Observation of the above marker-ratio plots, it may seem as though Figures 27 and 28 
might be the best candidates for the development of quality metrics, however these two 
plots show statistically significant differences between the groups for a majority of the 
data range even though little difference is observed in the “gold-standard” quality 
metrics (ALP and calcium) for the first several data points. Upon comparison of the 
above plots with the ALP activity and calcium deposition plots developed earlier 
(Figures 19 and 20; Section 3.1), it is worthy to note that both the ALP and calcium 
plots demonstrate similar trends for both groups through Day 7, diverging (to great 
extent) for only the last few time points, a trend which is most strongly mimicked by 
Figure 29, above for the ratio of OUR/GCR. Furthermore, this ratio has the greatest 
significance from a physio-metabolic standpoint based on the literature- and 
experimentally-supported shift in metabolism toward greater reliance on oxidative 
phosphorylation as MSCs differentiate into osteoblasts. For these reasons, the 
OUR/GCR ratio was selected as the most promising quality metric, to be discussed 
further in the following section. 
 
3.3.2       OUR/GCR Ratio as a Metric for Differentiation and Mineralization 
As mentioned previously, the OUR/GCR ratio establishes itself as a natural metric for 
cellular differentiation (and potentially “bone-like” formation) based on a metabolic 
shift in MSCs as they differentiate into osteoblasts. Additionally, utilization of the ratio 
of per-construct rates effectively negates the intrinsic unknown cellularity of the 
construct. The first trend to observe to verify its use in determining the quality of bone 
tissue engineered constructs is to compare it with current methods for such 
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determination: ALP activity and calcium deposition, such a comparison is provided in 
Figure 30, below (henceforth all plots were created for the entire data set without 
differentiation between the Osteo and MEM groups). 
The comparison afforded in Figure 30, below, reveals the existence of a clear 
demarcation between constructs exhibiting high calcium deposition and ALP activity 
and those not when plotted as functions of the OUR/GCR ratio. It is evident from the 
plot that a cutoff value of approximately OUR/GCR = 2.0 clearly differentiated between 
these two groups, with constructs exhibiting OUR/GCR ratios greater than 2.0 are very 
likely to have high osteoblastic differentiation (as evinced by high ALP activity) and 
high mineral deposition (as evinced by high calcium deposition), effectively 
representing well-developed bone tissue engineering constructs.  (The other ratios 
discussed in the previous section were attempted but did not reveal strong potential). 
 
Figure 30. OUR/GCR vs Traditional BTE Construct Quality Markers 
The ratio of OUR to GCR (plotted on the abscissa) vs the traditional bone tissue 
engineering construct quality markers of calcium deposition (on the primary ordinate; 
solid squares) and cellular ALP activity (on the secondary ordinate; open circles).  
Although there exists much noise in both data sets for low values of the OUR/GCR 
ratio, a clear demarcation can be made between low calcium and ALP activity levels 
corresponding to low ratios of OUR/GCR and high values of these markers 
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corresponding to high values of this ratio. As such, it appears as though an OUR/GCR 
ratio greater than ~2 strongly suggests high levels of calcium and ALP activity (thus 
relatively high occurrence of osteoblastic differentiation and mineral deposition). 
Values are presented as mean ± SEM (N=4 for Osteo, 3 for MEM). 
 
3.3.3 OUR/GCR Ratio as a Metric for Determination of Cellularity 
In order for this ratio to be well suited as a construct quality metric, it must be useful for 
more than the determination of the osteoblastic differentiation and mineralization of a 
construct (as Figure 30 demonstrates is has high potential for). Moreover, it must be 
useful in determining the cellularity of a construct, albeit itself independent of 
cellularity. In fact, this seemingly difficult requirement can be achieved indirectly via 
the utilization of the OUR/GCR ration to determine cell-specific rates (of either oxygen 
uptake, glucose consumption, or OPG production). If at least one of these cell-specific 
rates can be accurately determined from the OUR/GCR ratio, this rate can then be 
divided into its corresponding per-construct rate (able to be quantified in real-time non-
destructively) to determine constructs cellularity. With this in mind, Figures 31 and 32, 
below, compare the OUR/GCR ratio with the previously-quantified values of 𝑞𝑂2 and 
𝑞𝑔𝑙𝑐, respectively (a similar plot of OUR/GCR vs 𝑞𝑂𝑃𝐺 was attempted, but revealed no 
clear trends and so is not included). Both plots were fit with linear regression (based on 
observation of the relationship between the variables as seen in the figures). 95% 
confidence intervals were also provided as a means to visualize the accuracy of the fit. 
The resulting equations and r2-values for each fit are the following: 
 
 𝑞𝑂2(
𝑝𝑚𝑜𝑙
ℎ𝑟∗𝑐𝑒𝑙𝑙
) = 0.932 + 0.319 ∗ (
𝑂𝑈𝑅
𝐺𝐶𝑅
)                      𝑟2 = 0.47 (Eqn. 6) 
 𝑞𝑔𝑙𝑐(
𝑝𝑚𝑜𝑙
ℎ𝑟∗𝑐𝑒𝑙𝑙
) = 1.158 − 0.159 ∗ (
𝑂𝑈𝑅
𝐺𝐶𝑅
)                      𝑟2 = 0.56 (Eqn. 7) 
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Figure 31. OUR/GCR vs qO2 
The cell-specific oxygen uptake rate as a function of the per-construct OUR/GCR ratio. 
A fairly decent positive correlation exists, with the linear regression (bold black line) 
resulting in the following function: 𝑞𝑂2 = 0.932 + 0.319 ∗ (
𝑂𝑈𝑅
𝐺𝐶𝑅
) with an r2 = 0.47. The 
95% confidence interval is provided (dashed gray lines). Values are presented as mean 
± SEM (N=4 for Osteo, 3 for MEM). 
 
Figure 32. OUR/GCR vs qglc 
The cell-specific glucose consumption rate as a function of the per-construct OUR/GCR 
ratio. A decent negative correlation exists, with the linear regression (bold black line) 
resulting in the following function: 𝑞𝑔𝑙𝑐 = 1.158 − 0.159 ∗ (
𝑂𝑈𝑅
𝐺𝐶𝑅
) with an r2 = 0.56. 
The 95% confidence interval is provided (dashed gray lines). Values are presented as 
mean ± SEM (N=4 for Osteo, 3 for MEM). 
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Utilizing the linear regressions calculated from the above graphs (Equations 6 and 7, 
above), plots of the OUR/GCR – derived 𝑞𝑂2 and 𝑞𝑔𝑙𝑐 vs their experimental values were 
produced to better visualize the closeness-of fit. Said plots are provided below in 
Figures 33 and 34, respectively. Linear regression was again performed on these plots 
in order to analyze the slope and y-intercept of each as determinants of closeness-of-fit. 
Both regressions resulted in slopes of very nearly 1 with very small y-intercepts (<10-3). 
95% confidence intervals were again added to better visualize the accuracy of the fit. 
 
Figure 33. qO2 Curve-Fit vs. Experimental Values 
The OUR/GCR curve-fit cell-specific oxygen uptake rate vs. experimental values. The 
slope of the linear regression is 1.001, y-intercept is -1.11x10-3, r2 = 0.56. The 95% 
confidence interval is provided (dashed gray lines). Values are presented as mean ± 
SEM (N=4 for Osteo, 3 for MEM). 
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Figure 34. qglc Curve-Fit vs. Experimental Values 
The OUR/GCR curve-fit cell-specific glucose consumption rate vs. experimental 
values. The slope of the linear regression is 0.9998, y-intercept is -1.07x10-4, r2 = 0.56. 
The 95% confidence interval is provided (dashed gray lines). Values are presented as 
mean ± SEM (N=4 for Osteo, 3 for MEM). 
 
Finally, Equations 6 and 7 were used to calculate the cellularity of each construct as a 
function of only the per-construct OUR and GCR. The resulting equations for 
cellularity are given below as Equations 8 and 9, wherein the former was derived from 
the 𝑞𝑂2 = 𝑓 (
𝑂𝑈𝑅
𝐺𝐶𝑅
) curve-fit and the latter was derived from the 𝑞𝑔𝑙𝑐 = 𝑓 (
𝑂𝑈𝑅
𝐺𝐶𝑅
) curve-
fit. 
 𝑁𝑐𝑒𝑙𝑙𝑠 =
𝑂𝑈𝑅(
𝜇𝑚𝑜𝑙
ℎ𝑟
)
(0.932+0.319∗(
𝑂𝑈𝑅
𝐺𝐶𝑅
))
∗ 106 (Eqn. 8) 
 𝑁𝑐𝑒𝑙𝑙𝑠 =
𝐺𝐶𝑅(
𝜇𝑚𝑜𝑙
ℎ𝑟
)
(1.158−0.159∗(
𝑂𝑈𝑅
𝐺𝐶𝑅
))
∗ 106 (Eqn. 9) 
These equations were then plotted against the experimentally-obtained values of 
cellularity for each construct; linear regression was performed to determine fit. 
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Figure 35. Ncells from qO2 Curve-Fit (Eqn 8) vs. Experimental Values 
The cellularity of each construct calculated via Equation 24 vs. its experimentally-
determined cellularity. A linear regression (bold black line) resulted in a fairly decent 
fit, resulting in a slope of 1.30, y-intercept of -16100, and r2-value of 0.793. The 95% 
confidence interval is provided (dashed gray lines). The resulting confidence is 
approximately ± 20% of the calculated cellularity. Values are presented as mean ± SEM 
(N=4 for Osteo, 3 for MEM). 
 
Figure 36. Ncells from qglc Curve-Fit (Eqn 9) vs. Experimental Values 
The cellularity of each construct calculated via Equation 25 vs. its experimentally-
determined cellularity. A linear regression (bold black line) resulted in a fairly decent 
fit, resulting in a slope of 1.12, y-intercept of -14600, and r2-value of 0.796.  The 95% 
confidence interval is provided (dashed gray lines). The resulting confidence is 
approximately ± 20% of the calculated cellularity. Values are presented as mean ± SEM 
(N=4 for Osteo, 3 for MEM). 
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Both of these plots (Figures 35 and 36) reveal decent curve-fits, with r2-values very 
nearly 0.80. As such, the OUR/GCR ratio does prove to have high potential for the 
determination of the cellularity of a bone tissue engineered construct in real time 
without the need for its sacrifice. Although oxygen consumption data has been used by 
others as a means to quantify the cellularity of 3D tissue constructs, this was performed 
for non-differentiating constructs without a changing metabolic profile97. If there exists 
a change in the cell-specific oxygen consumption rate during the culture period as was 
experienced herein, then this method is no longer valid, necessitating such a method of 
non-destructively determining the cell-specific oxygen uptake rate (or other rates) as 
developed in this study. 
 
3.3.4 Summary of Quality Monitoring Metric Analyses 
Upon reviewing several candidates for the real-time non-destructive monitoring and 
determination of construct quality (defined herein as the combination of the degree of 
osteoblastic differentiation, amount of mineralization, and overall cellularity of said 
construct), the most propitious result was obtained via the intrinsically natural (if not 
obvious) ratio of OUR/GCR. Based on the physio-metabolic changes of MSCs as they 
differentiate into osteoblasts, this ratio has proven promising as a means for the 
determination of osteoblastic differentiation and construct maturation (as currently 
determined via ALP activity and calcium deposition). Furthermore, it seems to be a 
viable determinant of both cell-specific oxygen uptake and glucose consumption rates, 
which can subsequently be used to quantify the cellularity of a construct. Additionally, 
the OPGPR as well as the presence of osteocalcin may potentially be used to verify 
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OUR/GCR-based data, though methods for such protein detection are typically costlier 
both in terms of time and money, establishing these as better candidates for intermittent 
validation as opposed to continual monitoring. 
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4. CONCLUSIONS 
 
The studies presented herein have elucidated several aspects of bone tissue engineered 
constructs comprised of 85% porous spunbonded PLLA fibrous scaffolds seeded with 
rat MSCs and cultured in a flow perfusion bioreactor. Firstly, the flow profile through 
said constructs was determined via an analysis of residence time distributions to be well 
approximated by a plug flow model (study and results presented in the Appendix). The 
implications of this finding are not trivial, resulting in the validation of the assumption 
of negligible radial gradients in the flow profile and related shear stress and chemical 
species profiles. In other words, it implies that negligible differences in 
microenvironment should exist for all radial positions at a given axial coordinate, 
resulting in only axial gradients. With this conclusion, the velocity throughout the 
construct was determined to be approximately 0.42 cm/min, resulting in average wall 
shear stress values of approximately 0.017 dyne/cm2. Comparable to values reported by 
other groups, ranging from 0.001 to >10 dyne/cm2, such levels have been shown to 
positively influence osteoblastic differentiation98. 
Destructive post-culture construct analysis demonstrated successful development of 
bone tissue engineered constructs by Day 9 of culture in osteoinductive media. This 
claim is supported by sustained cellularity of 320,000 ± 30,000 cells per construct, and 
significant increases in ALP activity and calcium deposition to values of 3.0 ± 0.8 
pmol/cell/hr and 300 ± 100 ug, respectively. These values were determined to have been 
significantly higher than those for constructs cultured in non-osteoinductive media of 
1.2 ± 0.3 pmol/hr/cell and 70 ± 20 ug, respectively. Interestingly, the non-osteoinduced 
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constructs also exhibited significantly lower cellularity due to much greater detachment 
at early time points. Although the reasoning for this is not entirely known, it is 
hypothesized that it can potentially attributed to hypothetical higher binding affinity of 
osteoinduced MSCs as their attachment at a defect site is among the first steps in 
osteoblastic differentiation (whereas MSCs are typically present in vivo loosely bound 
in red bone marrow).  
Mid-culture physio-metabolic rates of oxygen uptake, glucose consumption, and OPG 
production, upon normalization with construct cellularity obtained from the 
aforementioned post-culture analysis, demonstrated key differences in trends observed 
for osteoinduced and non-osteoinduced cultures. Increases in the cell-specific oxygen 
uptake rate of osteoinduced MSCs over time to a value of 2.4 ± 0.3 pmol/hr/cell (by 
Day 14) were noted to be higher than that for their non-osteoinduced counterparts of 1.4 
± 0.6 pmol/hr/cell. Although these values are seen to be 10-20 fold higher than those 
presented in the literature, the overall trend of increasing 𝑞𝑂2 is supported
93,44,45. 
Gradual decreases were observed for the cell-specific glucose consumption rate for 
osteoinduced cultures to a value of 0.4 ± 0.1 pmol/cell/hr (by Day 14) as compared with 
the fairly constant value of 1.0 ± 0.4 pmol/cell/hr calculated for non-osteoinduced 
cultures. These values are in fairly good agreement with the literature, at approximately 
2-4 fold higher values, and the overall trend of decreasing 𝑞𝑔𝑙𝑐 is supported 
44,45,47,94. 
These trends, together, support the conclusion that osteoblastic MSCs observe an 
increased utilization of oxidative phosphorylation over their immature counterparts, as 
is well supported in the literature 43–46. Additionally, significant differences were 
observed for cell-specific OPG production rates with both cultures starting out with 
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rates around 0.8 ± 0.3 fg/hr/cell, a value which was fairly well-maintained by 
osteoinduced cultures exhibiting a value at Day 14 of 0.7 ± 0.2 fg/hr/cell whereas non-
osteoinduced cultures experienced rapidly-declining rates to steady levels of 0.1 ± 0.1 
fg/hr/cell. Although no literature values were available for cell-specific OPG production 
rates, the observation of higher rates for osteo-induced cultures as compared with non-
osteoinduced ones is supported 28,29,95,96. Lastly, osteocalcin secretion was detected only 
for osteoinduced cultures and only at late time points (Day 11 and Day 14), 
corresponding well with other observed trends, It is important to note that the literature 
values presented above were determined for cells cultured in stagnant 2D systems, 
possibly accounting for some of the differences in values obtained. 
Finally, comparative analyses enabled the development of potential monitoring schemes 
for the determination of the differentiation/maturation of bone tissue engineered 
constructs in addition to their cellularity. These focus primarily on the utilization of the 
ratio of the per-construct oxygen uptake and glucose consumption rates as a key 
indicator of said aspects. It has been concluded that a cutoff value of 2.0 for the 
OUR/GCR can serve as a reliable indicator of osteoblastic differentiation and “bone-
like” mineralization of a construct wherein values above 2.0 indicate such progression 
has occurred while those below 2.0 indicate a lack thereof. Furthermore, this OUR/GCR 
ratio has been shown to be a decently reliable method of determining cell-specific 
oxygen uptake and glucose consumption rates via correlation developed herein. 
Utilization of either (or both) of these rates can then be used along with the per-
construct oxygen uptake and/or glucose consumption rates to determine the cellularity 
of the construct in question. The importance of such a method allowing for reliable 
81 
quantification of cells within a construct in real time and non-destructively for 
constructs with changing metabolic profiles cannot be understated, as it has not 
previously been possible for such complex systems, as will be required in securing FDA 
approval for bone tissue engineering interventions as viable bone graft substitutes. 
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5. FUTURE DIRECTIONS 
 
The study herein has laid the foundation for meeting regulatory-mandated quality 
control of bone tissue engineered constructs. Further research, however, will be required 
to validate these results and broaden their applicability. First, the same study should be 
repeated for longer time points to ensure the developed correlations hold (or if new 
correlations need be developed to account for osteocytic differentiation at later time 
points). Moreover, further analyses of the sacrificed constructs could be performed to 
ensure their quality, such as PCR, histology, etc. Furthermore, more experiments 
varying initial cell seeding densities, seeding times, and flow rates should be performed 
to determine the effect of each on the maturation of constructs and their overall quality. 
Additionally, the monitoring of more potential marker molecules could result in more 
robust correlations, with lactate being a particularly obvious marker of choice (it was 
not studies herein as the FBS-supplemented media contains high levels of lactate 
dehydrogenase, adversely affecting the quantification of lactate; in order to overcome 
this, studies could be performed using serum-free, chemically-defined media). Finally, 
several groups have studied the effects of oxygen tension on the culture of MSCs 43–
46,54,94; the normoxic experiments presented herein could easily be adapted to an 
hypoxic setup with the simple replacement of oxygen-permeable tubing with non-
oxygen-permeable tubing. Comparison of results between both setups could help 
develop the literature, especially noting that a majority of studies of the metabolism of 
cells in vitro are based on 2D culture which has shown in many aspects to differ greatly 
from 3D culture. 
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Ultimately, the cells utilized herein would not be applicable to human intervention; as 
such, repeated studies with human MSCs should be conducted to develop correlations 
therein (which may vary drastically from rat MSCs). Furthermore, the principles 
established herein could easily be adapted for the monitoring of tissue engineered 
constructs other than bone, with the substitution of any of the markers utilized herein 
with those more relevant to changing physio-metabolic profile of the cells of choice. 
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APPENDIX 
 
A.1 Bioreactor Flow Profile Characterization 
The above rate-of-change equations allow for the quantification of the total drop in 
species concentration over time (or across the construct), but do not allow for the 
determination and/or prediction of the intra-construct species concentration profiles. In 
order to determine these, the flow profile through the constructs must be determined. 
This was achieved by performing a residence time distribution (RTD) analysis for the 
constructs. 
 
A.1.1 Residence Time Distribution Basics 
The method of residence time distribution analysis consists of injecting a tracer into the 
flow stream upstream of the construct chamber, and quantifying its concentration 
downstream of the chamber over time. For these studies, the tracer of choice was 
selected to trypan blue due to its ready dissolution in water, distinct absorbance peak at 
590 nm out to fairly dilute concentrations, and its potential for use in future 
experiments. 
Two predominant methods exist for such analysis: a pulse tracer input and a step tracer 
input. Each has its own benefits and disadvantages, and as such both were employed in 
order to best characterize the flow; each will now be discussed, in turn. 
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A.1.2 Pulse Tracer Input 
A pulse tracer input consists of injecting a small quantity of tracer into the stream for a 
short amount of time and observing the peak and subsequent wash-out of said tracer. 
This was achieved by utilizing two 3-way valves and an injection tip connected in series 
with the inlet tubing and creating two parallel flow paths, one of which is pre-loaded 
with the tracer and the other of which is open to the main flow line (as seen in Figure 
A1a, below). At time t = 0 both valves were turned to divert the flow through the tracer-
loaded channel, and samples were begun to be collected of the effluent of the construct 
chamber. Each sample consisted of 2 droplets obtained in approximately 22 seconds 
(resulting in approximately 55 µL of sample) collected in micro-centrifuge tubes. The 
experiment was allowed to run until the effluent was observed to have no remaining 
trypan blue. Experiments were run at a flowrate of 150 µL / min (the same flowrate 
used for the bioreactor experiments) with the use of the same peristaltic pump used for 
the bioreactor experiments (Langer Instruments, Model # BT100-1L). At the end of 
each run, 50 µL of each sample was loaded into a clear 96-well plate and subsequently 
run on a Synergy HT microplate reader (Bio-Tek) at an absorbance wavelength of 590 
nm. Controls were also run for the concentration profile exiting the injection tip (to 
allow for compensation of the delay from t = 0 to the actual time the tracer entered into 
the construct chamber) and for the profile through the empty cassette (without a 
scaffold, to determine the effect the scaffold plays in the flow profile). Multiple 
experiments were run for each condition. 
Raw absorbance values from the plate reader were corrected by subtracting a baseline 
absorbance of 50 µL of DI water at 590 nm. These corrected values constituted the 
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concentration profiles, c(t). Next, the residence time distribution function, E(t), and 
cumulative distribution function, F(t), were calculated in order to normalize all runs: 
 𝐸(𝑡) =
𝐶(𝑡)
∫ 𝐶(𝑡)𝑑𝑡
𝑡𝑓𝑖𝑛𝑎𝑙
0
 (Eqn. A1) 
 𝐹(𝑡) = ∫ 𝐸(𝑡)𝑑𝑡
𝑡
0
 (Eqn. A2) 
 Where 𝑡𝑓𝑖𝑛𝑎𝑙 is defined as the time at which 𝑐(𝑡) reached 101% of the 
  baseline DI water value 
 
Numerical integration using the trapezoid rule was employed in solving F(t).  
Then, the mean residence time, tm, and variance, σ2, were calculated for each run: 
 𝑡𝑚 = 𝜏 = ∫ 𝑡 ∗ 𝐸(𝑡)𝑑𝑡
𝑡𝑓𝑖𝑛𝑎𝑙
0
 (Eqn. A3) 
 𝜎2 = ∫ (𝑡 − 𝑡𝑚)
2 ∗ 𝐸(𝑡)𝑑𝑡
𝑡𝑓𝑖𝑛𝑎𝑙
0
 (Eqn. A4) 
Next, in order to relate the injection profile, empty cassette, and experimental runs, the 
dimensionless forms the residence time and cumulative distribution functions were 
calculated: 
 𝐸(Θ) = 𝜏 ∗ 𝐸(𝑡) (Eqn. A5) 
 𝐹(Θ) = ∫ 𝐸(Θ)𝑑Θ
Θ𝑓𝑖𝑛𝑎𝑙
0
 (Eqn. A6) 
 Where Θ =
𝑡
𝜏
 = dimensionless time 
 
Finally, the resulting functions were plotted and qualitatively analyzed against literature 
curves for a variety of flow reactor systems. 
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A.1.3 Step Tracer Input 
A step tracer input consists of a continuous injection of a tracer into the flow stream and 
observing the increase in tracer concentration until such time as the effluent 
concentration of the tracer is equal to that of the injected tracer. This was achieved by 
utilizing three 3-way valves connected in a Y-pattern (as seen in Figure A1d, below). 
The upper valves were connected in series to separate recirculation loops (one for a 
diluted tracer reservoir and one for a DI water reservoir). The lower valve was used to 
select either the water or the tracer as the injection fluid. At time t = 0 all three valves 
were turned to divert the selected injection fluid from the DI water to the tracer, and 
samples were begun to be collected of the effluent of the construct chamber. The 
experiment was allowed to run until the effluent was observed to have a tracer 
concentration equal to the inlet tracer concentration. Remainder of experiment was 
performed as described for pulse input (described above). 
Raw absorbance values from the plate reader were corrected by subtracting a baseline 
absorbance of 50 µL of DI water at 590 nm. These corrected values constituted the 
concentration profiles, c(t). Next, the cumulative distribution function, F(t), and 
residence time distribution function, E(t), were calculated in order to normalize all runs: 
 
 𝐹(𝑡) = 𝑐(𝑡)/𝑐0 (Eqn. A7) 
 𝐸(𝑡) =
𝑑
𝑑𝑡
(𝐹(𝑡)) (Eqn. A8) 
 Where 𝑐0 = tracer input concentration 
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Due to the step size and noise in the data, numerical differentiation was unsuccessful for 
calculating E(t). As such, c(t) was curve-fit utilizing a least-squares regression. The 
equation employed for the fit was selected to be of the form of Eqn. A9. In order to 
improve the fit, weighting factors were employed for the scaffold run (Eqn. A10). 
 𝑐(𝑡) = 𝑐0 −
𝑐0
1+(
𝑡−𝑡𝑏𝑡
𝐶1
)
𝐶2
  (Eqn. A9) 
𝑐(𝑡) = [𝑐0 −
𝑐0
1+(
𝑡−𝑡𝑏𝑡
𝐶1
)
𝐶2
] ∗ (1 − 𝑊) + 𝑐0 ∗ 𝑊 (Eqn. A10) 
 Where 𝑊 =
𝑡−𝑡𝑏𝑡
𝑡𝑓−𝑡𝑏𝑡
  
  𝑡𝑏𝑡 = breakthrough time (at which tracer was first detected in  
  effluent) 
  𝑡𝑓 = final time (when the effluent concentration reached 99% of  
   the input concentration) 
  𝐶1, 𝐶2 = curve-fitting parameters 
 
The resulting functions were then analytically differentiated to produce E(t). 
The remainder of the analysis was followed as described for the pulse input, above. 
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Figure 37. RTD Experimental Set-Up and Flow Diagrams 
Diagrams a. through c. represent the setup for the pulse input experiments. Diagrams d. 
through f. represent that for the step input experiments. Green arrows represent the flow 
paths for the pre-experimental (b. and e.) and experimental (c. and f.) setups. The blue 
circles represent 3-way valves with flow channels indicated in black. The blue 
trapezoids at the bottom of each diagram represent the injection tip. 
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A.1.4 Shear Stress Analysis 
Upon determining the flow distribution pattern throughout the construct, the velocity 
profile was subsequently calculated to be approximated by plug flow. Assuming the 
media behaves as a Newtonian fluid flowing at a constant velocity through a uniformly-
porous scaffold through cylindrical pores exhibiting laminar flow through each 
individual pore, the wall shear stress was calculated as: 
 𝜎𝑤 = −𝜇 ∗
𝑑𝑣𝑧
𝑑𝑟
|𝑟=𝑅 = −𝜇 ∗ (−2 ∗ 𝑣𝑚𝑒𝑑𝑖𝑎,𝑎𝑣𝑔 ∗
2
𝑅𝑝𝑜𝑟𝑒
) (Eqn. A11a) 
 = 
8∗𝜇∗𝑣𝑧
𝐷𝑝𝑜𝑟𝑒
 (Eqn. A11b) 
 Where 𝜇 = dynamic viscosity of media, 0.75 cp 
  𝑣𝑧 = average media velocity 
  𝐷𝑝𝑜𝑟𝑒 = pore diameter of construct, 250 µm  
 
The resulting values for the wall shear stress throughout the scaffold were compared 
with literature values as they pertain to osteoinductive effects.  
 
A.2 Results: Bioreactor Flow Characterization via RTD Analysis 
In order to better understand the flow characteristics within the flow perfusion 
bioreactor utilized within these experiments, residence time distribution analyses were 
performed. These allow for the determination of the flow profile(s) present within the 
reactor which subsequently allow for the estimation of shear stress and concentration 
profiles within the in vitro cultured constructs.  
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A.2.1 Pulse Tracer Input 
Three RTD experimental runs were performed with pulse tracer inputs at the bioreactor 
flow rate of 150 µL/min for each of the following setups: injection, open cassette, 
scaffold in cassette, and void-plugged scaffold in cassette. These setups were selected in 
order to best understand the individual contribution of each on the resulting RTD data, 
enabling for the deconvolution of the data obtained for the setup equal to that used in all 
cell-based studies. The injection runs represent the input concentration profile, the open 
cassette runs represent the flow through the cassette without any scaffold, the scaffold 
in cassette runs represent the experimental setup used for the cell-based studies, and the 
void-plugged scaffold in cassette represents the flow through the scaffold alone (with 
the void space above the scaffold in the cassette plugged, in order to determine the 
effect of this void space on the flow field). The resulting RTD and cumulative 
distribution functions are provided below in Figure A2 and Figure A3, respectively. 
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Figure 38. E(t) - Pulse Tracer Input 
Residence time distribution functions for pulse tracer inputs into bioreactor. Injection 
(solid circles) is the tracer input profile; open cassette (open circles) is the exit profile 
from the cassette without a scaffold; scaffold in cassette (solid triangles) is the exit 
profile from the cassette with a scaffold; void-plugged scaffold in cassette (open 
triangles) is the exit profile from the cassette with a scaffold with the void space above 
the scaffold plugged. The times corresponding to each peak, tpk, are 35 s, 55 s, 80 s, and 
65 s, respectively. The mean residence times, τ, associated with each function are 80 s, 
110 s, 185 s, and 200 s, respectively. Error bars removed to facilitate viewing, with 
average standard deviations of approximately 15%. 
 
 
Figure 39. F(t) – Pulse Tracer Input 
Cumulative distribution functions for pulse tracer inputs into bioreactor. Same 
experimental setups as described in Figure A2. The dashed horizontal line is located at 
F(t) = 0.95, representing the point at which 95% of the injected tracer had exited the 
reactor. The corresponding times for 95% tracer clearance, t95, for each function are 200 
s, 295 s, 525 s, and 545 s, respectively. 
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It is evident from Figures A2 and A3, above, that the tracer input deviates from the 
ideal Dirac delta function, exhibiting significant tail-right behavior due to the mode of 
injection. This non-ideal injection can be seen to affect the effluent profiles, though 
comparative analysis can still be accomplished with compensation. For a first 
approximation, this can be achieved by simply subtracting the relevant times associated 
with the injection profile from the times associated with effluent profile. The resulting 
corrected values are tabulated in Table A1, below. In order to better compare the flow 
phenomena, the E(t) and F(t) curves must be normalized by residence time; the resulting 
graphs are provided as Figures A4 and A5, below. 
 
Raw Values Corrected Values 
𝑡𝑝𝑘 (𝑠) 𝜏 (𝑠) 𝑡95 (𝑠) 𝑡𝑝𝑘
∗  (𝑠) 𝜏∗ (𝑠) 𝑡95
∗  (𝑠) 
Injection 35 80 200 0 0 0 
Empty Cassette 55 110 295 20 30 95 
Scaffold 80 185 525 45 105 325 
VP-Scaffold 65 200 545 30 120 345 
Table 5. Characteristic Times for RTD Curves 
Characteristic times listed are the time associated with the peak E(t) value, the mean 
residence time, and the 95% tracer clearance time. Corrected values obtained by 
subtracting corresponding values for Injection profile from each other profile’s values. 
 
The corrected characteristic times for each of the experimental setups suggest differing 
flow phenomena experienced within each. The low 𝑡𝑝𝑘
∗  values for each setup 
demonstrate the presence of significant levels of dispersion within the system. The low 
𝜏∗ and 𝑡95
∗  values for the empty cassette suggest significant channeling (due to the 
concentric alignment of the entrance and exit and lack of any flow distributor). 
Comparing the scaffold and void-plugged scaffold runs it is evident from the 𝑡𝑝𝑘
∗  values 
that the void-plugged scaffold contains a smaller liquid volume (being displaced by the 
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plug). Additionally, the 𝜏∗ and 𝑡95
∗  values suggest the presence of more back-mixing 
within the void-plugged scaffold. This could potentially be explained by the lack of a 
flow settling region (afforded by the void above the scaffold) in the void-plugged 
scaffold, causing the formation of internal eddies due to the direct injection of the tracer 
into the center of the top of the scaffold. 
 
Figure 40. E(θ) - Pulse Tracer Input 
Normalized residence time distribution functions for pulse tracer inputs into bioreactor. 
Same experimental setups as described in Figure A2. The θ values corresponding to 
each peak are 0.45, 0.50, 0.42, and 0.33, respectively. Error bars removed to facilitate 
viewing, with average standard deviations of approximately 15%. 
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Figure 41. F(θ) - Pulse Tracer Input 
Normalized cumulative distribution functions for pulse tracer inputs into bioreactor. 
Same experimental setups as described in Figure A2. All curves exhibit the same 
tailing behavior, but key differences are present in the range from 0-τ. 
 
Figures A4 and A5 demonstrate the similarity between all the experimental setups, all 
representing high dispersion within the system. Notably, the void-plugged scaffold is 
seen to exhibit a delayed, steeper, and narrower initial peak than the other systems, 
demonstrative of potential channeling as a result of the lack of a flow settling region (as 
described previously). Overall, the comparative analysis of the pulse tracer inputs 
suggests the presence of plug flow with high dispersion within all setups, though the 
significant tailing in the tracer input could be confounding the analysis. As such, step 
tracer input experiments were performed on the standard scaffold-in-cassette system to 
better elucidate the flow regime(s) present within the bioreactor. 
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A.2.2 Step Tracer Input 
Three RTD experimental runs were performed with step tracer inputs at the bioreactor 
flow rate of 150 µL/min for the injection profile and the scaffold in cassette setups 
described in the previous section. The resulting concentration data was curve-fit, the 
resulting equations and parameters are provided in Table 4, below. This equation was 
then used to produce F(t), which was analytically differentiated to obtain E(t). The E(t) 
and F(t) curves for both setups are provided below in Figure A6 and Figure A7, 
respectively.  
The normalized residence time and cumulative distribution functions are provided in 
Figure A8 and Figure A9, respectively, to better compare the two functions. 
 
 
Equation 
Parameters 
tbt C1 C2 tf 
Injection 
𝑐(𝑡) = 𝑐0 −
𝑐0
1 + (
𝑡 − 𝑡𝑏𝑡
𝐶1
)
𝐶2
 
15 19.3 2.48 - 
Scaffold 
in 
Cassette 
𝑐(𝑡) = [𝑐0 −
𝑐0
1 + (
𝑡 − 𝑡𝑏𝑡
𝐶1
)
𝐶2
] ∗ (1 − 𝑊) + 𝑐0 ∗ 𝑊 
𝑊 =
𝑡−𝑡𝑏𝑡
𝑡𝑓−𝑡𝑏𝑡
  
90 110.3 1.39 1100 
Table 6. RTD Step Input Curve-Fitting Parameters 
Curve-fit equations and parameters used for step input RTD c(t) curves. W is the 
weighting factor used to improve the fit for the scaffold-in-cassette run, c0 is the 
concentration of the tracer injected, tbt is the breakthrough time, tf is the final time (at c 
= 99% of c0), and C1 and C2 are curve-fitting parameters. 
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Figure 42. E(t) – Step Tracer Input 
Residence time distribution functions for step tracer inputs into bioreactor. Injection 
(solid circles) is the tracer input profile; scaffold in cassette (open circles) is the exit 
profile from the cassette with a scaffold. The times corresponding to each peak, tpk, are 
30 s and 115 s, respectively. The mean residence times, τ, associated with each function 
are 36 s and 162 s, respectively. Error bars removed to facilitate viewing, with average 
standard deviations of approximately 8%. 
 
 
Figure 43. F(t) - Step Tracer Input 
Cumulative distribution functions for step tracer inputs into bioreactor. Same 
experimental setups as described in Figure A6. The dashed horizontal line is located at 
F(t) = 0.95, representing the point at which 95% of the injected tracer had exited the 
reactor. The corresponding times for 95% tracer clearance, t95, for each function are 80 
s and 590 s, respectively. 
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Figure 448. E(θ) - Step Tracer Input 
Normalized residence time distribution functions for step tracer inputs into bioreactor. 
Same experimental setups as described in Figure A6. The θ values corresponding to 
each peak are 0.84 and 0.71, respectively. Error bars removed to facilitate viewing, with 
average standard deviations of approximately 8%. 
 
 
Figure 45. F(θ) - Step Tracer Input 
Normalized cumulative distribution functions for step tracer inputs into bioreactor. 
Same experimental setups as described in Figure A6. Both curves demonstrate similar 
breakthrough θ values and general overall shape, with more significant tailing observed 
for the scaffold in cassette setup. 
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A much cleaner injection profile was achieved by the step input mode as opposed to the 
pulse input, exhibiting far less tailing, facilitating the effluent analysis of the reactor 
system. Significant tailing is still observed in the scaffold in cassette system, resulting 
in much higher 𝑡∗ values: 𝑡𝑝𝑘
∗  = 85 s, 𝜏∗ = 126 s, and 𝑡95
∗  = 510 s. These, along with the 
much higher peak-associated θ-value for the bioreactor system strongly support the 
conclusion that the flow regime through the scaffold is well approximated as plug flow 
with significant dispersion. This conclusion is further buttressed upon comparing the 
E(θ) curve with a plug-flow with dispersion model curve from Levenspiel (side-by-side 
comparison provided in Figure A10). 
 
Figure 46. Comparison of RTD Data with Literature 
A plot from Levenspiel’s Chemical Reaction Engineering for the plug flow with 
dispersion model for various amounts of dispersion (a.) compared with the E(θ) 
function obtained from a step tracer input RTD experiment (b.). The great similarity 
between these two plots supports the conclusion that the flow profile through the 
scaffold is plug flow with dispersion. (Figure A10a copied from 99). 
 
a. b. 
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A.2.3 Determination of Shear Stress 
Based on the plug flow profile determined above, utilization of Equation A11b results 
in uniform initial wall shear stress values throughout the construct of approximately 
0.017 dyne/cm2. Although this value is on the lower end of those used by other groups, 
ranging from 0.001 to >10 dyne/cm2, such low levels have still been shown to promote 
osteoblastic differentiation of MSCs 98. As cells proliferate and deposit mineral, the 
pores will necessarily narrow (and become less homogenous), thereby resulting in 
increased wall shear stress values in addition to greater variability of such values 
throughout the construct. As such, it is beneficial to start at low shear stress values, 
allowing for increases throughout the culture period to still sustainable levels. 
 
A.2.4 Summary of Flow Profile Analysis 
Based upon the data presented in the above sections, it was concluded that the flow 
through the scaffold within the bioreactor is well approximated as plug flow with 
dispersion. Furthermore, it is theorized that the void space above the scaffold may act as 
a flow settling region, allowing for the distribution of species and momentum prior to 
entering the scaffold, thereby resulting in uniform species concentrations and flow 
velocities across the entrance to the scaffold. As such, it is concluded that a plug flow 
velocity distribution is appropriate to model the flow through the reactor (with 
modifications for the scaffold and cell impedance), which along with the assumption of 
uniform cell distribution throughout the scaffold (or at least a uniform distribution for 
all radial positions at a given axial coordinate) allows for the elimination of radial 
concentration gradients in both species concentrations and shear stress distributions. 
